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Abstract 
Background:  Non-adherence to medications is a major concern among patients with type 2 
diabetes mellitus (T2DM). Failure to achieve positive health-related outcomes could be 
associated with non-adherence. Medication non-adherence is considered a socio-behavioral 
problem, thus using a behavioral model such as the transtheoretical model (TTM) could 
improve it.  
Objective: The primary objectives of this study were: (1) to determine the TTM’s Stages of 
Change (SOC) and medication adherence scores of patients with T2DM in a primary health 
care setting in Qatar; (2) to determine the relationship between these two variables; and (3) to 
determine whether SOC could predict medication adherence whilst controlling for 
confounding factors. The secondary objectives were to assess the relationship: (1) between 
SOC and glycated hemoglobin (HbA1c); and (2) between medication adherence and HbA1c 
in the same population. 
Method: The study was conducted in the non-communicable disease clinic. Non-Qatari 
patients were recruited from Mesaimeer Health Care Center, whereas Qatari patients were 
recruited from Westbay Health Care Center.  Medication adherence was measured using the 
eight-item Morisky Medication Adherence Scale (MMAS-8), and SOC was determined using 
a two-item SOC questionnaire. HbA1c values were obtained from the electronic medical 
records at the clinic. Spearman rank correlation was conducted at α level of 0.05 to determine 
the relationship between variables of interest, and hierarchical regression was performed to 
determine if SOC could predict medication adherence, while controlling for confounding 
factors. 
Results: A total of 387 patients were included in the analysis. The majority of the participants 
were non-Qatari (84.8% non-Qatari vs. 15.2% Qatari). The highest percentage of participants 
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was in the maintenance stage (76.7%). The rate of low, medium, and high adherence to 
antidiabetic medications was 26.4%, 23.3%, and 50.3%, respectively. There was a significant 
positive correlation between SOC and adherence score (r= 0.728, p < 0.001), and SOC was 
able to significantly explain 58 % - 59 % of the variance when predicting medication 
adherence % (p < 0.001) while controlling for confounding factors. 
Conclusion: There was a strong association between SOC and medication adherence, 
suggesting that the two-item SOC questionnaire could potentially be used as a simple tool to 
identify patients at risk of low adherence.  
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Chapter 1: Introduction 
1.1 Diabetes epidemiology worldwide and in Qatar 
Many health organizations worldwide consistently highlight the importance of health 
promotion and disease prevention due to the high incidence and prevalence of several chronic 
diseases which continues to rise with time. In the last 20 years, the prevalence of diabetes 
mellitus (DM) has greatly increased in several parts of the world and it is currently 
considered a global public health problem (1). In 2012, DM was the cause of 1.5 million 
deaths which meant that every seven seconds a person died due to DM. More than 80% of 
these reported deaths were in low and middle income countries (2). In 2014, the global 
prevalence of DM in adults was estimated to be 8.5 % (3). There are currently around 387 
million people living with type 2 diabetes mellitus (T2DM) worldwide, and the prevalence of 
the disease is projected to escalate to 592 million people by 2035. The number of people with 
T2DM is currently increasing in every country. In the Middle East and North Africa (MENA) 
region, 37 million people have T2DM, a figure estimated to rise to 68 million by 2035 (4). 
T2DM caused 368000 deaths in 2013 in the MENA region alone, and 50% of these deaths 
were in individuals under the age of 60 (4). 
Qatar is a country which is currently experiencing an alarming increase in prevalence 
of T2DM. Qatar is a Middle Eastern country and it is part of the Gulf Cooperation Council. It 
has been a part of the International Diabetes Federation (IDF) since 1997. In 2015, Qatar had 
239,100 cases of T2DM (13.5% of the adult population between the ages of 20 and 79 years 
old) (5). Figure (1) illustrates the prevalence of Diabetes in Qatar compared to the MENA 
region and the rest of the world in 2014. 
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Figure 1: Diabetes prevalence in adults based on age groups in Qatar, MENA, and the world 
(6) 
1.2 Economic burden of diabetes 
In 2014, DM was responsible for at least USD 612 billion dollars in global health 
expenditure (4). Focusing particularly on the MENA region, USD 17 billion dollars (3% of 
the total worldwide expenditure) was spent on treating DM (4). The annual cost per person 
with diabetes in Qatar is estimated to be USD 2,868 dollars. There are approximately 16.5 
million people with T2DM in the U.S, and their annual national cost is about USD 159.5 
billion (7). In addition, there are 6.3 million adults with undiagnosed DM in the United States 
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of America (USA) who are unaware that they have the disease. These individuals are left 
untreated and their associated cost was estimated to be USD 18 billion in 2007 (8). Nearly 57 
million adults have pre-diabetes: a state of elevated blood glucose which is a precursor to 
diabetes. Pre-diabetes is associated with USD 25 billion annually in higher medical costs (9). 
The vast DM-related spending currently imposes a substantial burden on the global economy 
in the form of increased medical and indirect costs from absenteeism from work, reduction in 
productivity and labor force due to chronic disability, and premature mortality (10, 11). 
T2DM is specifically costly when patients begin to develop other associated chronic 
complications. In 1997, there were some data on complications associated with T2DM in the 
USA, but the results could not be extrapolated globally (11). However, several studies 
conducted later found that the cost of managing patients with uncontrolled T2DM or patients 
with diabetes complications was at least two to eight times more than that of managing 
patients with controlled or non-advanced diabetes (12, 13). T2DM increases the risk of 
developing several serious neurological, peripheral vascular, cardiovascular, renal, metabolic, 
and ophthalmic complications (11). While, the direct medical costs attributed to treat T2DM 
was USD 27 billion diabetes, the cost of treating chronic complications attributed to it was 
about USD 58 billion (11). 
1.3 Diabetes treatment and self-management 
Diabetes is a metabolic chronic disease which if left untreated, can affect the entire 
body systems and lead to a worse health-related quality of life (HR-QOL). It occurs when a 
person has a high concentration of glucose in the blood either because the pancreas does not 
produce enough insulin, or because the body cannot use insulin properly (14). According to 
the World Health Organization (WHO), a person is diagnosed with diabetes if the plasma 
glucose concentration is higher than 11.0 mmol/l after 2 hours of ingesting 75 grams oral 
glucose load, or/and if after fasting overnight, the plasma glucose concentration is ≥ 7.0 
4 
 
mmol/l, or/and if A1C is ≥ 6.5% (15, 16). There are three types of diabetes; gestational 
diabetes which is temporary and occurs during pregnancy, type 1 diabetes which occurs when 
the immune system of a person destroys the beta cells in the pancreas, and type 2 diabetes 
which occurs when the cells in the body are resistant to insulin or if the body is unable to 
produce sufficient insulin to control metabolic activities (17). T2DM is the most common 
type, and its’ risk factors are obesity and lack of exercise especially in people who are 
genetically predisposed (18). Once developed, T2DM cannot be cured, but non-
pharmacological strategies along with medications are necessary to manage the disease and 
delay its progression (19). Usually patients with T2DM do not need insulin as a treatment and 
instead they rely on oral antidiabetic medications including: metformin, sulphonylureas, 
glitazones, gliptine, repaglinide, or a combination of these (20). If patients with T2DM are 
unable to self-manage their disease, they will be at a higher risk of developing diabetes 
associated complications including cardiovascular diseases, retinopathy, nephropathy, 
neuropathy, and in some cases amputation of the lower limbs (21). In the USA alone, 28.5% 
of patients with T2DM have retinopathy, and 44% of all nephropathy cases were due to 
T2DM. Additionally, 65% of patients with T2DM aged 18 years or older suffered from 
dyslipidemia (22). Therefore, the ability to self-manage the disease is of paramount 
importance in improving HR-QOL in patients with T2DM. 
Even though self-management of diabetes is the most crucial factor that contributes to 
the therapy’s success and subsequently leading to a better HR-QOL, many patients still have 
a problem in being able to self-manage their disease.  The main objectives of Diabetes Self-
Management Education (DSME) are to encourage and aid patients in informed decision-
making, self-care behaviors to improve clinical outcomes, and quality of life (23). Self-
management of diabetes requires numerous activities that the patient needs to perform 
regularly. It requires patients to follow a healthy diet with no smoking or alcohol 
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consumption, exercise regularly, and adhere to their medications as prescribed in order to 
achieve optimum glycemic control. It is also very important for patients with T2DM to 
monitor their blood glucose levels regularly. Due to the complexity of T2DM, and the need to 
make daily self-care decisions, focusing on adherence alone is not sufficient (24). Since there 
was a relationship between knowledge, attitude and practice (KAP) and DM, many DSME 
now include providing patients with the knowledge, abilities, and skills needed for self-care. 
In addition, for any educational intervention to be successful, it must incorporate the needs, 
goals, and life experiences of the patients with T2DM to engage and encourage them to self-
manage their disease.  
The World Health Organization guideline for a national program for diabetes 
emphasized the importance of educating patients with T2DM to help them attain a healthy 
quality of life and delay the disease progression as well as development of further 
complications (25). Many studies conducted in developed countries proved that lifestyle 
changes in patients resulted in a reduction in the prevalence of diabetes (26). However, there 
still seems to be a gap between the expected care and that provided by diabetes care teams, 
and the only way to close this gap is to conduct multidisciplinary interventions to achieve 
better HR-QOL (27).  
The treatment of diabetes has advanced tremendously in the past several years, but 
many patients are still unable to achieve the desired clinical outcomes, and as a result suffer 
from a worse quality of life. Poor clinical outcomes are mainly because health care 
professionals depend solely on the biomedical model, which treats patients as passive 
recipients of doctors’ instructions to treat chronic conditions (28, 29). This model provides a 
mechanistic view of any illness and it requires health care professionals to carry out 
mechanical solutions such as prescribing the correct medicine with the correct dose for the 
patient. Its main emphasis is on diagnosing and treating patients to return them to their pre-
6 
 
illness stage. Clinicians who apply this model believe that the problems of non-adherence to 
medications are due to certain characteristics in patients (30). However, the WHO, defines 
health as “a state of complete physical, mental, and social wellbeing, and not merely the 
absence of a disease or infirmity” (31). Since the biomedical model mainly focuses on 
improving physical wellbeing and not the remaining aspects of health, interventions began 
incorporating socio-behavioral models along with the biomedical to holistically improve 
personal health according to the WHO’s definition. 
Over the years, several socio-behavioral models were developed to describe the 
mental and social well-being of patients. Social models of health focus on policies, education, 
and health promotion in order to address the broader influences on health such as 
environmental, cultural, or economic influences. Since the inability to self-manage diabetes is 
a complex socio-behavioral problem, adding a behavioral context might help patients control 
their diabetes leading to better clinical outcomes. Many social and behavioral models were 
used to promote self-management, but none were effective in diabetes care (32). However, 
one of the behavioral models known as the Transtheoretical Model (TTM) seems promising 
in supporting patients with T2DM.  
1.4 The transtheoretical model 
In the 1980’s, James O. Prochaska and Carlo C. DiClemente developed the TTM in 
an attempt to understand how people intentionally modify a certain behavior (33). The TTM, 
also known as the Stages of Change (SOC) model, is a socio-behavioral model that is 
commonly used in research and clinical practice. It is an integrative model of intentional 
change which explains how people acquire a positive behavior or change their unhealthy 
behavior by focusing on the decision making process of the individual. The TTM was 
originally used to focus on smoking behavior, but due to its popularity, it has been tested with 
several other behaviors such as weight loss (34), cancer screening behavior (35), and 
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encouraging stroke victims to exercise (36). According to the TTM, changing an undesirable 
behavior is a long time dependent cognitive process. The TTM consists of 4 components: 
stages of change, processes of change, decisional balance, and self-efficacy. 
1.4.1 Stages of change 
Stages of change (SOC) can be conceptualized to either change or stop a specific 
undesirable behavior. The SOC are classified into: precontemplation, contemplation, 
preparation, action, and maintenance. The progression through SOC is not necessarily linear, 
and people move through these stages similarly to a cyclical pattern. Thus, individuals may 
regress to previous stages before moving forward. The following points describe each SOC of 
the TTM according to Prochaska et al. (1994) (37): 
(i) Precontemplation stage: Individuals do not have the desire to change their behavior in 
the next 6 months. People at this stage are uninformed about changing certain 
behavior. Usually those at this stage will only consider changing their behavior if a 
significant person encourages them, or they are threatened in their life due to that 
behavior (e.g. might lose a job or a partner). If an individual says no to changing 
his/her behavior then he/she are considered to be in the precontemplation phase, but in 
order for those individuals to move forward in the cycle they must recognize and 
acknowledge their unhealthy behavior. 
(ii) Contemplation stage: Individuals are aware that they have a problem with their 
behavior and they start thinking about the possibility of changing, but they have not 
yet made a commitment to change. Individuals at this stage start to search for ideas 
and facts in order to contemplate the idea of changing, and they weigh out the rewards 
and losses that will occur as a result of their behavior change. People at this stage 
know what they want to change already, but they are still not ready to do so. They 
plan to change within the next six months. 
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(iii) Preparation stage: Individuals at this stage will change in the near future (usually in 
the next month).This stage combines both intention and behavior strategies. 
(iv) Action stage: Individuals have actively changed their unhealthy behavior. A person is 
considered at this stage when he/she has successfully changed their old habit and 
adopted a new healthy one instead for around one to six months. This stage requires a 
behavioral modification and a commitment of energy and time to change the problem 
behavior. Individuals at the action stage must adopt effective strategies to sustain the 
behavior. 
(v) Maintenance stage: Individuals at this stage changed their behavior and have been 
practicing the new one for more than six months. Individuals at this stage must focus 
on developing reinforcement strategies to sustain the new behavior and prevent 
relapse. 
1.4.2 Processes of change 
Processes of change are defined as activities that people need to follow in order to 
alter their experiences or surrounding environments to modify their behavior (37). There are 
ten processes of change which are divided into cognitive and experiential and behavioral. In 
the cognitive and experiential processes, information is created based on people’s own 
experiences or actions, whereas in the behavioral processes, behavioral strategies are used to 
change the undesirable behavior. The cognitive and experiential processes are consciousness 
raising, dramatic relief, self-reevaluation, environmental reevaluation, and social liberation. 
The behavioral processes of change are self-liberation, counterconditioning, reinforcement 
management, helping relationships, and stimulus control. The following points describe the 
processes of change used in the TTM according to Prochaska et al. (1994) (37): 
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(i) Consciousness raising: This process is used to move individuals from 
precontemplation to contemplation. It requires people to gather new information 
about a certain behavior in order to have a better understanding of it. Interventions 
which could increase the awareness or knowledge of the individuals include 
feedback and interpretations to support the healthy behavior change. 
(ii) Dramatic relief: It is used to move patients from contemplation to action.  It 
involves emotional experiences which are related to the changes in behavior. 
Interventions implementing dramatic relief can provide fear that becomes 
associated with the old behavior, or success stories about other people who 
already changed their behavior in order to be inspired by them. 
(iii) Environmental reevaluation: It is used to move patients from contemplation to 
preparation. The individuals start to notice how their behavior affects their social 
environment.  People at this stage begin to recognize that they can serve as either 
a positive or negative role model for others. 
(iv) Self-reevaluation: This process moves people from contemplation to preparation.  
The individual starts to consider the cognitive and emotional values related to 
their behavior so they could assess their self-image with or without the specific 
unwanted habit. 
(v) Social liberation: It is used to change patient from precontemplation to action. 
Individuals begin to realize that changing behavior is possible and is acceptable in 
the society. It helps people realize that social norms are supporting their healthy 
behavior. 
(vi)  Self-liberation: It is used to move people from preparation to maintenance. The 
individuals start to develop a new mindset that encourages them to change and 
commit to their new healthy behavior. 
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(vii) Counter conditioning: it is used to change individuals from action to maintenance. 
It requires people to learn new behaviors as substitutes for their undesirable 
behavior. 
(viii)  Helping relationships: It is used to change individuals from action to maintenance 
stages. Individuals rely on others to support them during their attempts to change 
their behaviors. Encouraging calls and rapport building are some of the activities 
which could be used as sources of social support. 
(ix) Reinforcement management: It is used to change patient from action to 
maintenance.  It provides rewards to people when they change their undesirable 
behavior and punishments if they practice it. People usually have very high 
expectations about people encouraging them, so it is important that they 
encourage themselves by saying self-statements such as “good job… you were 
able to resist the temptations”. 
(x) Stimulus control: It is used to change individuals from action to maintenance. It 
removes any cues or reminders related to old behavior, instead uses cues that 
remind people to engage in their new behavior. 
1.4.3 Self-efficacy 
The self-efficacy component in the TTM is based on Bandura’s theory which states 
that “successful change is based on the increased level of confidence an individual 
demonstrates in coping with different tempting situations without relapsing” (38). Self-
efficacy involves self-confidence of an individual in order to resist the temptations and be 
able to maintain their new behavior. As individuals move forward through the stages of 
change, self-efficacy should increase and the temptations decrease. 
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1.4.4 Decisional balance 
Decisional balance assesses the advantages and disadvantages of adopting the new 
desirable behavior. Usually, individuals who are at the early SOC believe that the cons of 
changing their behavior are more than the pros of changing, but as individuals move forward 
across the SOC, the pros begin to outweigh the cons. There is usually a crossover between the 
pros and cons at the contemplation, preparation and action stages (39), and the strategies that 
help people move along the continuum from precontemplation to contemplation to 
preparation should work primarily on decreasing the cons. 
1.5 Medication adherence 
Medication adherence is a term that describes the extent to which patients take their 
medications as recommended by their health care professionals. Although, the terms 
medication adherence and compliance are considered the same for majority of people, they 
have different meanings in actual practice.  Previously, the term medication compliance was 
described as the act of taking medications on schedule and as prescribed, whereas medication 
adherence was the act of filling new prescriptions or refilling prescriptions online (40).  Many 
researchers felt that the term compliance gave an impression that doctors and other health 
care professionals order patients to take their medications in a specific way, and hence the 
term adherence is now commonly used in its place (41). The following are the most common 
techniques currently used separately or together to measure medication adherence (42):  
1) Objective measurements which are obtained by assessing the pharmacy refill records, 
counting pills, or by using electronic medication event monitoring systems. 
2) Subjective measurements which are obtained by asking questions related to the 
patient’s medication use patterns to the patient, family members, or the health care 
professionals. 
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3) Biochemical measurements which are obtained by incorporating a nontoxic marker to 
the medication taken and detecting its presence in blood or urine or measurement of 
serum drug levels. 
 
The most common indirect method of measuring medication adherence used in 
clinical settings is patient self-reported measures. There are questionnaires which have a high 
degree of agreement with electronic medication monitoring devices (43), and they are a way 
to measure medication adherence both simply and effectively (44, 45). Medication adherence 
scales are usually validated and compared to an objective measure of medication adherence 
before they are given to different patient populations with different disease conditions. A 
good medication adherence scale should be able to identify the beliefs, barriers or behavior of 
the patients regarding taking their medications, and it needs to be very accurate and precise 
(46). The problem with these self-reported questionnaires is that patients could misinterpret 
the information in it and distortion of some results could occur by patient themselves (47). 
There are many medication adherence self-reported measures used in clinical settings 
including Beliefs about Medication Questionnaires (BMQ) (48), Adherence Self-Report 
Questionnaire (ASRQ) (49), Medication Adherence Rating Scale (MARS) (50), and the most 
commonly used Morisky Medication Adherence Scale (MMAS) which was developed in 
1986 (51). The original MMAS scale has four items with dichotomous responses of either 
Yes or No. The reason the four items were chosen was because “the drug errors of omission 
could occur in any or all of several ways: forgetfulness, carelessness, stopping the drug when 
feeling better or starting the drug when feeling worse” (51). It was first validated in an 
outpatient setting to measure adherence to antihypertensive medications (51). The problem 
with the four items original scale was that it did not show good psychometric properties. It 
had specificity and sensitivity of 44% and 81% respectively, and a Cronbach’s alpha 
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reliability of 0.61, which is considered below the acceptable value of 0.7. However, the 
original scale was still used in a lot of studies that identified medication adherence scores for 
multiple medications until a modified scale was developed in 2008. The new scale was an 
eight-item Morisky Medication Adherence Scale (MMAS-8) (52). The first seven items 
require dichotomous responses of either Yes or No, and the last item is a five point likert 
response. The added four items in the modified scale identify the situations related to 
medication taking behavior, and it was found to have better psychometric properties 
compared to the original scale: sensitivity and specificity of 93% and 53%, respectively, and 
a Cronbach’s alpha value of 0.83 which is above the acceptable value (52). According to 
Muntner et al. (2011), a change of two or more in the MMAS-8 score in a person before and 
after an intervention is considered a significant change of medication adherence behaviors 
(53). The original Morisky Scale and the modified one both have advantages compared to the 
other questionnaires used to measure medication adherence such as it could be used in 
different countries, on different populations and various diseases since it was translated and 
validated in several foreign countries. Furthermore, they have a high degree of concordance 
with electronic monitoring devices and pharmacy fill data. They also have fewer items 
compared to other self-report measures which results in less burden on the patients. However, 
they both have a few drawbacks such as they do not allow a comprehensive evaluation of the 
medication adherence behavior, so it would be difficult to develop a well-designed 
intervention that aims to enhance medication adherence (54). 
Uncontrolled T2DM can lead to severe complications such as retinopathy, 
nephropathy, neuropathy, hypertension, and dyslipidemia, and a worsened HR-QOL. 
Preventing those complications will not only be beneficial to patients, but it will also reduce 
the overall health care expenditure (55). One of the most common reasons for uncontrolled 
DM is non-adherence to medications. Good health-related outcomes cannot occur if patient 
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does not take their medications consistently (56).  Another common reason for uncontrolled 
T2DM is that health care professionals in most institutions still use the biomedical model to 
treat patients even though it has failed to improve clinical outcomes and HR-QOL. Since the 
biomedical model has failed, and non-adherence to medications is considered a behavioral 
problem, health care professionals have started using socio-behavioral models such as TTM 
to improve medication adherence.  
1.6 Study rationale 
There is currently an alarming increase in the prevalence of T2DM among the adult 
population in Qatar, and this trend is expected to continue for the next few years unless 
appropriate strategies are put in place. Since most patients with T2DM in Qatar primary 
health care setting are uncontrolled, there will most likely be a high prevalence of diabetes-
associated complications (57). As a result, there is more spending on diabetes, more 
economic burden, and an increase in morbidity and mortality rates. The primary reason for 
uncontrolled diabetes is non-adherence of the patients to their prescribed medications which 
is often associated with higher costs to treat T2DM (58). In fact, non-adherent patients can 
have annual inpatient costs of 41% higher than adherent patients suggesting that significant 
costs could be avoided if patients were adhering to their prescribed medications (59).  The 
present study was conducted because there is currently no available data describing the 
medication adherence patterns in patients with T2DM in a primary health care setting in 
Qatar. Since non-adherence to medications is considered a socio-behavioral problem, using a 
behavioral model such as the TTM could address this issue. Before developing and 
implementing any TTM intervention to encourage patients with T2DM to adhere to their 
medications, it is important to determine the SOC and medication adherence scores of the 
patients and to determine if there is an association between these variables.  If medication 
adherence could be improved in patients using TTM interventions, then more patients would 
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likely have controlled diabetes resulting in a reduction in glycated hemoglobin (HbA1c), 
better HR-QOL, and a significant reduction of costs spent to treat diabetes. Previous studies 
suggested that the efficacy of medication adherence interventions might be improved by 
applying the SOC theory of behavior change (60-62). Thus, the association between the SOC 
and medication adherence using MMAS-8 was determined in patients with T2DM attending 
primary health care clinics in Qatar.  
1.7 Study objectives 
The overall goal of the study is to assess whether the TTM stages of change is 
applicable to medication adherence in adult patients with T2DM in Qatar primary health care 
setting. Whether or not TTM SOC fits the target population will help us better understand the 
use of the model in a developing country, as well as yield possible intervention strategies to 
help enhance adherence in those who are not adhering to their medications. Once the SOC of 
an individual patient is correctly identified, then stage specific intervention strategies will be 
applied to help the individual progress through the SOC toward adopting a positive 
behaviour. The above goal would be achieved through the following specific objectives: 
i. To determine the SOC of adult patients with T2DM in a primary health care 
setting. 
ii. To measure the medication adherence scores of patients with T2DM. 
iii. To evaluate the relationship between the SOC and medication adherence while 
controlling for confounding factors. 
iv. To evaluate the relationship between SOC and glycemic control while 
controlling for confounding factors. 
v. To evaluate the relationship between medication adherence and glycemic 
control while controlling for confounding factors.  
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1.8 Significance of the study findings  
To our knowledge, this will be the first study evaluating the association between 
TTM’s SOC and medication adherence in patients with T2DM in the MENA region. The 
findings will provide evidence on whether TTM’s SOC is a strong predictor of medication 
adherence, and HbA1c, and determine if there is an association between medication 
adherence and HbA1c in patients with T2DM. The findings of this study are of significance 
since they will help us understand the medication adherence patterns and SOC of patients 
with T2DM in a primary health care setting in Qatar. Once the targeted relationships are 
established, the TTM intervention which incorporates the ten processes of change would be 
applied to those with low adherence and earlier SOC. The potential intervention will be of 
major significance to patients as it will help them enhance their medication adherence which 
would in return lead to better clinical outcomes including reduction in HbA1c, and a better 
HR-QOL. It will also help patients achieve a controlled diabetes status which would 
minimize the risks of developing diabetes-related complications, and reduce the risk of 
hospitalization. In addition, it would also provide benefits to the healthcare system, especially 
at primary health care level. If the TTM is proven to be significantly effective, it will 
tremendously reduce healthcare expenditure for managing diabetes and its related 
complications, since the setting would have less emergency department (ED) visits and future 
admissions related to the disease. Finally, if TTM was able to accomplish these outcomes, 
then it could be part of primary health care clinics’ policy and practice to help patients with 
T2DM manage their disease and achieve a better control of diabetes. 
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Chapter 2: Review of Literature 
2.1 What is already known? 
For many years, health care professionals have relied on the biomedical model in 
managing patients with T2DM to encourage them to adhere to their antidiabetic medications. 
However, since this model focused on only one aspect of health according to the WHO 
definition of health, diabetes burden began to significantly increase over the years, and a 
more promising strategy to address the issue of non-adherence was highly needed. Since non-
adherence to medications is a behavioral problem, socio-behavioral models such as TTM 
started to evolve in an effort to address the problem. It is important that patients with T2DM 
adhere to their prescribed medications to be able to achieve a better control of their disease. 
The government of Qatar would also have less health care expenditure on the disease if it is 
controlled, and if there is a low incidence of its associated complications. Although the use of 
TTM to predict medication adherence was not previously tested in a population with T2DM, 
it seems promising as TTM’s ability to predict medication adherence was previously 
evaluated in other chronic conditions. For example, it was able to predict medication 
adherence in patients with HIV (63). Moreover, identifying the SOC of patients with T2DM 
regarding following a healthier diet, and exercising more regularly, was determined in 
previous studies. The investigators reported that TTM was able to help patients with T2DM 
follow a healthier diet, and exercise more. However, the study did not investigate the 
relationship between SOC and medication adherence or the effect of TTM on the adherence.  
This chapter explains in details how TTM was used in previous studies among patients with 
T2DM. 
2.1.1 Self-management of diabetes 
Several self-management interventions emerged for patients with T2DM to be able to 
manage their condition, and daily life activities. Many approaches were identified during the 
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development of educational interventions to strengthen the beliefs to self-manage their 
diabetes, and to control the disease (64). Lifestyle guidelines and increasing patients’ 
knowledge about diabetes are both important to self-manage diabetes, but they are not 
adequate to achieve appropriate behavioral changes (65 ).  Several research studies conducted 
globally focused on health promotion, and disease prevention due to increasing prevalence of 
chronic diseases which have multifactorial etiologies including a social component (66, 67).   
Systematic reviews and meta-analyses conducted previously provided evidence that 
implementing a self-management intervention which incorporates educational or behavioral 
strategies could enhance the ability of patients with T2DM to self-manage their condition and 
increase target behavior actions such as following a healthier diet, blood glucose monitoring, 
following medical appointments and increasing physical activity (68, 69). Moreover, various 
studies were conducted to determine the most appropriate method to encourage patients with 
T2DM to adhere to a prolonged regime of self-management. These studies which utilized 
behavioral or educational strategies reported significant improvements in glycemic control 
(67, 70-74), but the improvements decreased gradually overtime in two studies (72, 74). Two 
studies reported that the baseline values of HbA1c had an effect on the reduction of glycated 
hemoglobin post the self-management intervention, in which there was a greater reduction 
when the baseline values of HbA1c were higher (67, 75). There is no evidence that self-
management interventions are able to reduce mortality or morbidity among patients with 
T2DM, hence there is a need to study the impact of those interventions on long-term and 
definitive outcomes (73).  One study which evaluated patient education found that behavioral 
outcomes rather than physiological outcomes should be rewarded in order to maintain self-
management activities (76). Moreover, a previous study by Moser et al. (2008) evaluated 
interventions which were conducted to enhance self-management activities of patients with 
T2DM. The study reported that all the interventions evaluated consisted of dynamic and very 
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complex set of processes which all need to be implemented in each patient’s unique life 
situation (75). Multiple lifestyle modifications are needed in order to self-manage diabetes 
(77). Other factors such as patient involvement (78), family involvement (79), cultural 
adaptation (80), and individualization (81) were also found to be important in the 
development of self-management interventions. 
2.1.2 Previous use of TTM 
TTM could be used to enhance several self-management activities since it is a socio-
behavioral model. Although it was first introduced to help smokers quit (82), TTM 
interventions were later applied on several other populations to enhance their behavior.  
According to a study by Gong et al. (2015), a TTM intervention reduced blood pressure, 
stroke and heart attack incidents in patients with hypertension (83). Similarly, some studies 
were conducted to determine the effect of TTM interventions on patients with myocardial 
infarction. The results indicated that TTM approach had a significant positive effect on 
exercise (84), reduced fat intake in Dutch patients who were at high risk of cardiovascular 
events (85), and it helped patients quit smoking (86). Additionally, interventions using the 
model helped breast cancer survivors follow a healthier diet, and exercise more (87), and 
motivated women to enhance Pap smear uptake (88). In a study by Fahs et al. (2013) TTM 
improved the diet, and lowered the blood pressure of women living in rural areas (89). 
2.1.3 Previous use of MMAS-8 
              Several studies were conducted in various populations to assess the psychometric 
properties of MMAS-8. One study in Italy tested its predictive value for increased ambulatory 
arterial stiffness index (AASI) in a population with hypertension, and it reported that MMAS-
8 is a strong predictor of AASI (90). The MMAS-8 questionnaire was also validated in 
patients with irritable bowel diseases (IBDs) in which prescription claim data was correlated 
with MMAS-8, and the results suggest that 85% of the subjects who were identified as 
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patients with low adherence by MMAS-8 had non persistent fill rates compared with 11% of 
medium and high adherers (91). MMAS-8 was also validated in a population with T2DM. 
The validation in that population indicated that MMAS-8 had three dimensions which are 
forgetting to take medications, stopping medications when feeling better or worse, and the 
complexity of the drug regimen, and it suggested that MMAS-8 could be used to assess 
medication adherence in diabetes (92). Another study was conducted to determine the 
correlation of MMAS-8 with pharmacy prescription refill data in community dwelling seniors 
with hypertension, and findings suggested that MMAS-8 had a significant association with 
antihypertensive drug pharmacy refill adherence (93). MMAS-8 was used to identify 
medication adherence in some interventions which were conducted to enhance adherence. 
One study was done to evaluate the effectiveness of a trained community health workers’ 
(CHW) intervention among Hispanic people who were newly diagnosed with T2DM and the 
intervention was able to enhance medication adherence (94). Another study assessed the 
effectiveness of a lifestyle intervention on systolic blood pressure (SBP), and medication 
adherence which was measured using MMAS-8 in minority elderly people with hypertension. 
The intervention was successfully able to reduce SBP, and enhance medication adherence 
(95).  
2.1.4 TTM and medication adherence 
Over the past years, studies were conducted to determine the ability of TTM to 
enhance medication adherence.  TTM has been used to measure the SOC regarding 
medication adherence in patients receiving antihypertensive medications (96). In another 
study conducted among patients with hypertension, individuals who received the TTM 
intervention had higher medication adherence to their antihypertensive medications at 12 and 
18 months of the intervention as compared to their counterparts who received usual care 
(73.1% of participants in the intervention group were at the action or maintenance stages after 
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12 months, as compared to 57.6% in the control group, and 69.1% in the intervention group 
versus 59.2% in the control group at 18 months) (97). TTM-based interventions have also 
been shown to improve medication adherence, diet, and exercise in individuals taking lipid 
lowering drugs (98). Participants in the treatment group who were at pre-action stages 
(precontemplation, contemplation, preparation) before the intervention, moved to action and 
maintenance stages regarding their medication adherence post the TTM intervention, and 
there was significant improvement in exercise, and dietary fat reduction compared to the 
control group (56% versus 37.8% for medication adherence, 43.3% versus 24.7% for 
exercise, and 24.7% versus 12.5% for diet). Furthermore, two studies were conducted to 
evaluate the effectiveness of TTM on medication adherence in patients with HIV who were 
actively taking antiretroviral therapy (ART) (63, 99). A study by Genberg et al. (2013) 
reported an association between TTM and medication adherence which was determined using 
electronic monitoring devices. The study also stated that those at the earlier SOC had 
significantly lower adherence compared to those at the later SOC (action or maintenance 
stages) (63). Another study suggested that incorporation of the social, behavioral, and 
cognitive aspects of TTM is necessary for an intervention to enhance medication adherence 
in patients taking highly active antiretroviral therapy (HAART) (99). 
           Another study used TTM to predict interferon beta-1a-Biogen (known as Avenox
®
) 
treatment discontinuation in people with multiple sclerosis. Pros and cons of Avenox
®
 
treatment, highest educational qualification obtained, and the extent of disability were the 
major factors which led 82% of the participants to discontinue Avenox
®
 (100). The study 
supported the use of TTM to determine patients with multiple sclerosis who were not 
adherent to their medications and help them improve it. Moreover, TTM was recommended 
to be used as a screening tool to identify patients with HIV (63), and multiple sclerosis (100) 
who are not adhering consistently to their prescribed medications. 
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          Corelli et al. (1999) highlighted the importance of pharmacists to use TTM to help 
patients with T2DM manage their disease. The study stated that if pharmacists could 
determine each patient’s SOC regarding all behaviors associated with diabetes, they would be 
able to help patients self-manage their diabetes and achieve better clinical outcomes (101). So 
far, TTM was used in interventions on patients with T2DM to assess its ability to motivate 
patients to exercise regularly and to follow a healthier diet with less salt and fat consumption. 
It was never studied to determine if there is an association between SOC and medication 
adherence in patients with T2DM. TTM interventions helped patients with T2DM move 
forward through the SOC regarding exercise as compared to patients in the control group 
receiving usual care (102-104). TTM also helped patients with T2DM follow a healthier diet 
(103, 105), which involved using herbs instead of salt, cooking with canola or olive oil, using 
artificial sweeteners in baking (106). There was also a significant reduction in fat intake in 
patients with T2DM after the TTM intervention was implemented (107). Other studies tested 
the ability of TTM interventions to reduce HbA1c in patients with T2DM, and results suggest 
that due to the different processes of change applied, TTM was able to cause a significant 
reduction in HbA1c (102, 103, 105, 108).  
2.1.5 Reasons for non-adherence to medications 
Non-adherence to medications could have a negative impact on clinical outcomes in 
patients with T2DM, and could lead to an increase in mortality rates. The WHO suggests that 
if medication adherence could be increased for chronic conditions such as diabetes, the health 
outcomes would improve significantly, and the health economic burden would decrease 
(109). The WHO classified the factors which cause a decrease in medication adherence into 
five different categories: socioeconomic factors, patient-related factors, factors associated 
with the health care team and health care system, disease-related factors, and therapy-related 
factors (109). The following section describes these factors in more details: 
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(i) Socio-economic factors: These usually include time commitment, cost of therapy, 
income and social support. Time commitment means that patients sometimes 
might not be able to take some time off their work for treatment or clinic visits 
and as a result their adherence could be influenced (110-112). To address this 
issue, a study suggested that a shorter traveling time for patients between their 
homes and their health care providers could enhance medication adherence (113). 
In addition, cost of therapy is a major issue that influences medication adherence 
especially for chronic diseases since the treatment is prescribed for a much longer 
time (112, 114). Health care costs are not considered a big burden if the patient 
has a high income. In fact, studies have found that patients with low income were 
more likely to be non-adherent to their medications compared to those with high 
income (115-117). Finally, social support from family members, friends, and 
health care providers helps patients adhere to their treatment mainly because their 
support reduces the negative attitudes to treatment, and provides constant 
motivation and reminders to take their medications (118-121) 
(ii) Patient-related factors: These include lack of involvement in the decision making 
process which determines the patient’s medication regimen (122), and lack of 
understanding the disease condition (123). Another factor that contributes to 
medication non-adherence is health literacy (124). About 90 million adults in the 
USA have inadequate health literacy (125), which results in more incidences of 
hospitalization, and poor clinical outcomes (126, 127). Other patient-related 
factors, which influence medication adherence behavior, are the patient’s health 
attitudes and beliefs regarding the prescribed medications, previous treatments 
patients received, and the extent of motivation to adhere to their pharmacological 
therapies (47, 128, 129). 
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(iii) Health care team and health care system-related factors: The absence of an 
effective communication between a physician and a patient can affect the patient’s 
understanding of the disease and its associated complications. The absence of 
communication between health care professionals and patients would lead to 
undermining the importance of adhering to medications from the patient’s 
perspective (130). In primary health care clinics and hospitals, the direct effective 
communication is present in less than 20% of the cases, and the discharge 
summaries are available at less than 34% of first discharge visits (131). Thus, a 
poor health care system, which lacks effective communications between 
physicians and patients could limit patients’ access to care, and create several 
barriers to medication adherence (132). Moreover, unaffordable drug costs and co-
payments result in a poor medication adherence (133, 134). If a health care system 
is overtaxed and receives a large number of patients without having the resources 
or time to treat them, this could result in poorer medication adherence due to the 
lack of time to discuss its importance and the possible methods to improve it. 
(iv) Disease-related factors: Good health outcomes would never be achieved if patients 
are not consistently taking their medications as prescribed (56). Non-adherence to 
medications could be intentional or unintentional (135), and adherence is usually 
better if the regimen is simpler (136). Approximately 50% of patients with chronic 
diseases do not take their medications as prescribed (109, 137). Focusing 
particularly on patients with T2DM, their reported adherence to medications 
ranges from 36% to 93% worldwide (138). Adherence is usually determined on 
the basis of the patient’s clinical outcomes (139). Therefore, strict glycemic 
control would be a surrogate indicator of good medication adherence (140).  
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(v) Therapy-related factors: The route of administration could tremendously affect 
medication adherence. For example, patients with asthma have better compliance 
to oral medications as compared to inhalers (141, 142). Treatment complexity is 
also an important factor because the higher the frequency of daily dosing for all 
prescribed medications, the lower the medication adherence (143-145). Side 
effects also threaten adherence to prescribed medications (146-148). A study 
conducted in Germany indicated that the second most common reason to non-
adherence to antihypertensive medications was the side effects associated with the 
medications (149). Treatment duration is another factor that influences adherence 
to medications as patients with longer disease duration could have better 
adherence to medications (150, 151). 
2.1.6 SOC and HbA1c 
Several studies were conducted to test the relationship between SOC and HbA1c. For 
example, a study reported that for patients with T2DM attending primary care, advancement 
in SOC for diet, led to better glucose control and higher levels of continuity of care with the 
primary care providers (152).  Another study compared HbA1c values in a TTM intervention 
group with those of patients in a control group receiving usual care.  After the TTM 
intervention, the study indicated a significant reduction in HbA1c in the intervention group as 
compared to the control group (105).  Three other studies proved the effectiveness of the 
TTM intervention in encouraging patients with T2DM to follow a healthier diet, and exercise 
more regularly which subsequently led to a significant reduction in HbA1c (102, 103, 108). 
2.1.7 Medication adherence and HbA1c 
              Many studies found that there is a direct relationship between medication adherence 
and HbA1c, where higher adherence is associated with a reduction in HbA1c. One study 
suggested that for each 10% increment in drug adherence, HbA1c decreases by 0.16% even 
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after controlling for demographic characteristics and disease duration (153). The study also 
highlighted that African Americans had poorer medication adherence and higher HbA1c as 
compared to Caucasians. Better medication adherence was also associated with lower HbA1c 
even after controlling for age, gender, race, BMI, disease duration, and diabetes therapy 
(154). In addition, a review of the literature reported that most studies involving patients with 
T2DM showed an association between medication adherence and HbA1c regardless of the 
tool used to measure adherence, but interestingly the association was not always apparent at 
low income populations (155). 
2.2 What does the research add to existing knowledge? 
              The SOC and medication adherence patterns in patients with T2DM in a primary 
health care setting in Qatar were not previously investigated. Therefore, this is the first study 
of its kind to determine these variables in Qatar primary care setting. Earlier studies 
suggested that there was an association between TTM and medication adherence for chronic 
conditions such as HIV (63), and that TTM could be used to enhance medication adherence 
in patients with hypertension (97).  Even though TTM seems to be associated with 
medication adherence in some chronic populations, that relationship was not studied in 
patients with T2DM worldwide. So far, TTM was only used in studies involving patients with 
T2DM to help them follow a healthy diet, and exercise regularly. The present study will 
therefore identify medication adherence scores of patients with T2DM in a primary health 
care setting in Qatar to determine the prevalence of non-adherence to medications in this 
target population. It will also determine the SOC of patients with T2DM regarding their anti-
diabetic medications, and assess the relationship between the SOC and HbA1c. If a positive 
relationship between the SOC and medication adherence in patients with T2DM is proven, 
then that would conclude that SOC is associated with self-management activities of T2DM. If 
SOC can also predict medication adherence in our target population, then the two-item SOC 
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questionnaire could be used as a screening tool instead of the longer MMAS-8 to identify 
patients with T2DM who are not adhering to their medications, and encourage them to 
receive a TTM intervention to enhance their adherence. 
2.3 Research conceptual framework 
Figure (2) shown below is a conceptual framework describing the associations to be 
determined between several variables of interest in the study. The main objective as stated 
previously is to determine the relationship between SOC and medication adherence, SOC and 
HbA1c, and medication adherence and HbA1c. Additionally, the study will also determine if 
demographic characteristics, disease duration, and total prescribed medications are associated 
with SOC, medication adherence, or HbA1c. 
 
 
 
 
 
 
Figure 2: Conceptual framework describing the associations to be explored between the 
variables in the study 
 
2.4 Primary hypotheses 
The following hypotheses will be tested in this study: 
1) We hypothesize that SOC will be positively associated with medication adherence, 
while controlling for confounding factors. We expect that patients at pre-action stages 
(precontemplation, contemplation, and preparation) will have low or medium 
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adherence and those at late SOC (action and maintenance) will have high medication 
adherence. This is expected because patients who claim are adherent to medications, 
should have more advanced SOC regarding consistently taking their prescribed 
medications. 
2) We also hypothesize that earlier SOC will be negatively associated with HbA1c, 
while controlling for confounding factors. Participants at the early SOC 
(precontemplation, contemplation, and preparation) would have higher HbA1c levels, 
whereas those at advanced SOC (action and maintenance) would have lower HbA1c 
levels. This is anticipated because patients who are at the late SOC might have been 
compliant to their medications for a long time and therefore should have lower 
HbA1c levels. 
3) Lower medication adherence will also be negatively associated with HbA1c, while 
controlling for confounding factors, since patients with T2DM who are taking their 
prescribed medications regularly should ideally have lower HbA1c. This implies that 
patients with low adherence scores would have high HbA1c levels, while those with 
high adherence score would have low HbA1c levels. 
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Chapter 3: Methodology 
3.1 Study design 
This was a cross-sectional observational study involving adult patients with T2DM in 
a primary health care setting in Qatar. A questionnaire to identify SOC regarding medication 
adherence, and a tool to measure medication adherence were both administrated to every 
participant recruited as part of the study sample. HbA1c was the main clinical outcome 
recorded for all patients recruited.  
3.2 Ethics approval 
The research study was approved by the Primary Health Care Corporation (PHCC) 
with a reference number “PHCC/RC/15/05/008” (see Appendix A) and Qatar University’s 
Institutional Review Board with a reference number “QU-IRB 593-A/16” (see Appendix B). 
All recruited participants were given a participant information and informed consent sheet 
(see Appendix C) to help them understand the nature and procedure of the study, and they 
were asked to sign the consent upon agreeing to participate. Participants were allowed to 
withdraw from the study at any time they desire. 
3.3 Study setting and timeline 
The PHCC was the chosen setting to conduct this study since it is known to receive 
the largest number of patients with T2DM in Qatar. The PHCC was established as an 
independent corporation in 2012, and it currently consists of 21 primary health care centers 
which are located in central, northern, and western parts of Qatar. Since the PHCC regularly 
receives a high number of visitors (5.2 million visits in 2014), more primary health care 
center are expected to open soon. In order to keep up with the increasing number of patients 
and to serve that large population, 12 new health care centers are expected to open by 2019 
(156).  The PHCC offers a wide range of services including pharmacy services, mental 
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health, laboratory services, and health education. All the services provided by the PHCC aim 
to shift the balance of care from a curative model towards a preventive and community based 
model. Two PHCC centers were selected as study sites. Mesaimeer Primary Health Center 
was chosen because it has a high percentage of patients with T2DM attending the non-
communicable diseases (NCD) clinic and Westbay Primary Health Center was chosen since it 
has a high number of Qatari patients attending the NCD clinic regularly. The recruitment of 
participants began on 7 February 2016 and ended on 28
 
April 2016.  
3.4 Study population and sampling 
The target population from which the study participants were selected was adult 
patients with T2DM in Qatar. In 2015, there were approximately 239,100 adults with T2DM 
in Qatar (157), and 43,466 of those were Qataris, hence representing 18% of the target 
population (158). This indicates that there were 195,634 (82%) non-Qatari patients diagnosed 
with T2DM in Qatar. The sample size was calculated proportionately to be representative of 
the target population. The formula used to calculate the required minimum sample size for 
the study was: n = Z1-α/2
2 
p (1- p)/ d
2 
(159). Z1-α/2
 
is the standard normal variate which is 
considered 1.96, since the type I error was set at 5%, p is the expected proportion of adult 
patients with T2DM in Qatar which is 13.5%, and d is the absolute error or precision which 
was set at 5% . Substituting the variables in the formula, n = 1.96
2 
x 0.135 x (1-0.135)/ 
0.0025 = 180. Therefore, the minimum sample size required was 180 patients with T2DM.  A 
total of 387 patients with T2DM were recruited from both centers with the number of Qataris 
and non-Qataris in the sample proportionate to the target population. The method of sampling 
was convenience sampling. However, in order to obtain a random sample the researchers 
randomly selected 10-15 patients every day at the NCD clinic out of a total of around 40 
patients attending the clinics daily. Those selected were approached for their consent to 
participate in the study. Out of the non-Qataris attending the NCD clinic in Mesaimeer 
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Primary Health Center, 328 patients with T2DM participated in the study, whereas 59 Qatari 
patients from Westbay Primary Health Center participated in the study. These numbers were 
representative of the target population. All participants were recruited during their regular 
scheduled visits, and none were requested for any further follow-up related to the research. 
The inclusion criteria for the study were: (i) adults with confirmed T2DM diagnosis (HbA1c 
≥ 6.5%, FPG ≥ 126 mg/dl, and/or 2h plasma glucose ≥ 200 mg/dl); and (ii) prescribed oral 
antidiabetics, and/or insulin. The exclusion criteria were: (i) age < 18 years old; (ii) pregnant 
women, because diabetes could be gestational; (iii) mentally incompetent patients, as mental 
defects might affect the ability to correctly understand the questionnaires administrated; and 
(iv) receiving only on non-pharmacologic therapy (i.e. lifestyle modifications). Figure (3) 
describes the sampling procedure for the patients recruited from each clinic for the study. 
 
 
 
 
            
            
            
            
Figure 3: Flowchart for sampling patients with T2DM from the target population for the 
study. 
Mesaimeer 
Primary Health 
Center 
328 non-Qatari patients 
(85%) 
59 Qatari patients 
(15%) 
Target population of patients with T2DM 
Partial simple random sampling 
Westbay Primary 
Health Center 
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3.5 Study confounding factors 
Other variables which could be confounding factors were determined and placed in 
the data collection tool in order to control for those which significantly impacted SOC, 
medication adherence or HbA1c. Based on a thorough literature search, the potential 
confounding factors recorded were disease duration, total number of prescribed medications, 
and demographic characteristics including age, gender, marital status, nationality, ethnicity, 
highest educational attainment, and occupation (26). 
 
3.6 Development and validation of SOC questionnaire 
The SOC questionnaire was used to determine patient’s SOC regarding their 
adherence to anti-diabetic medications. The tool was available and validated in English, and 
translated to Arabic for the participants who preferred to use the Arabic version. The English 
version consisted of two previously validated survey items (160) (see Appendix D). The 
questionnaire was validated in patients with HIV, and patients with hypertension, but the 
results suggested that it could be used to determine the SOC about medication adherence for 
patients with any other chronic conditions (160). Upon validating the questionnaire, construct 
validity was demonstrated by associations between the SOC and previously validated 
measures of adherence (P<0.001), and the predictive validity was supported by significant 
associations between the SOC for medication adherence and medication adherence score 
(P<0.03) (160). Since the SOC questionnaire was not available or validated in Arabic, the 
English version was translated using forward translation, followed by backward translation, 
pre-testing, and cognitive interviewing in order to obtain the final version of the Arabic 
questionnaire (see Appendix E). 
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3.7 Development and validation of MMAS-8  
MMAS-8 was the tool used to assess medication adherence of the recruited 
participants from both centers. The English version (see Appendix F) was developed in 2008 
from the original four-item Morisky scale (52). The first seven items are dichotomous 
response categories of either Yes or No. The seven items include questions about:  (i) 
forgetting to take medicine; (ii) how many days did a patient forget to take the medications 
over the past 2 weeks; (iii) if the patient stopped taking their medications; (iv) whether the 
patient forgets to take the medicine when they leave home or travel; (v) whether they took 
their medicine yesterday; (vi) if the patient forgets to take their medications  if he/she feels 
like their symptoms are under control; and (vii) if the patient feels hassled about following 
their treatment plan. The last item on the scale has a five-point Likert response in which 
patients describe how often they have difficulty remembering to take medications (i.e. 
never/rarely, once in a while, sometimes, usually, or all the time). The English version of 
MMAS-8 was validated in other chronic diseases such as hypertension (52), where it showed 
strong reliability (α= 0.83), sensitivity and specificity of 93% and 53%, respectively. The 
Urdu version of the scale was also validated in 2012 (see Appendix G) (161). It had a 
Cronbach’s alpha of 0.701 which is considered within the acceptable range (162), and its 
specificity and sensitivity were 46.15% and 60%, respectively. The Arabic version of 
MMAS-8 was also used in this study (see Appendix H). It was validated in 2015, and it 
demonstrated a Cronbach’s alpha of 0.7. All the corrected item total correlations were 
optimal (0.34 - 0.51), except for the fifth item which had the lowest corrected item total 
correlation (r = 0.25), but removing it did not significantly improve the alpha value (0.71). 
The Arabic version of MMAS-8 had a sensitivity and specificity of 63.9%, and 82.3%, 
respectively (163). 
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3.8 Development and validation of the data collection tool 
The data collection form was designed to obtain all relevant patient information for 
this study. It consisted of the following nine sections respectively: (i) demographic profile 
which included PHCC identification number, date of birth, age, gender, marital status, 
nationality, ethnicity, educational attainment, and occupation; (ii) date of diabetes diagnosis; 
(iii) date of first visit with DM diagnosis at NCD; (iv) comorbidities; (v) number of 
medications for other chronic conditions; (vi) stage of change; (vii) medication adherence; 
(viii) clinical outcomes; and (ix) medication regimen for T2DM (see Appendix  I). 
3.9 Outcomes measured and tools used 
The main outcomes of interests were participants’ SOC, medication adherence scores, 
and HbA1c. The SOC about adherence to anti-diabetic medications was measured using the 
two-item SOC questionnaire. The first item placed participants in precontemplation, 
contemplation, preparation, or action and maintenance stages. The second item differentiated 
between individuals at action and maintenance (160). Medication adherence of patients with 
T2DM was measured using MMAS-8, which provides scores ranging from 0 to 8. Scores 
were classified as follows: (i) low adherence if the score from 0 to 5.75; (ii) medium 
adherence if the score was between 6 and 7; and (iii) high adherence if the score was 8. 
MMAS-8 is a self-reported measure, and the weakness of such measures is that there is often 
some social desirability bias upon using them.  
In order to ensure that social desirability bias while using MMAS-8 was not a 
prominent limitation, an objective method was used to calculate medication adherence for 
participants who had sufficient data. This was done to check if the other measure will give 
similar adherence results as those obtained from MMAS-8. Two of the commonly used 
objective measures of adherence are medication possession ratio (MPR) and proportion of 
days covered (PDC) (164). MPR formula is (the sum of the days' supply for all fills of a 
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given drug in a particular time period / the number of days in the time period) × 100. 
However, PDC which is a newer and more conservative objective measure of adherence is 
(number of days in the period covered / the number of days in the time period) × 100.  The 
major issue with MPR is that it sometimes overestimates adherence because some patients 
refill their medications early, hence they will have an inflated MPR. PDC considers this, and 
makes an adjustment if a patient refills his/her medications prior to running out of it since it 
incorporates in the formula the days covered, not supplied. In addition, PDC is recommended 
for medication regimens such as multiple medications for diabetes and it considers the days 
within a particular period only when a patient is covered for all medications in a 
regimen. Although MPR is more commonly used, PDC is becoming the preferred adherence 
measurement because of its advantages as outlined above. Therefore, PDC was the objective 
measure chosen in this study to compare its adherence scores with those obtained from 
MMAS-8, where a percentage of 80% or higher obtained from PDC is considered high 
adherence.  
HbA1c was extracted from each patient’s electronic health record available at the 
electronic database. Based on the American Diabetes Association (ADA), the HbA1c values 
were later categorized into 2 groups: controlled diabetes status if a patient had HbA1c of ≤ 7 
%, or uncontrolled diabetes status is if the HbA1c was > 7 % (165). 
3.10 Data collection procedure 
Patients attending the Non-Communicable Diseases Clinic (NCD) at Mesaimeer and 
Westbay Primary Health Centers were requested to answer the SOC, and MMAS-8 
questionnaires. The items in the questionnaires were read along with all possible answers to 
the patients in English, Arabic, or Urdu based on their preference. Moreover, HbA1c and 
FPG were obtained from each patient’s health record available at the electronic database. 
Information about each patient’s medication’s start date, dose, and frequency, number of total 
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prescribed medications along with the date of their first visit in the NCD clinic was extracted 
from each patient’s paper-based medical record. Some demographic characteristics; age, 
gender, ethnicity, nationality were obtained from each patient’s health record from the 
electronic database available at both clinics. Ethnicity was categorized into: Arab, Asian, or 
Others, whereas the nationality was divided into either: Qatari or Non-Qatari. The remaining 
demographic characteristics; marital status, latest educational attainment, and occupation 
were not available in the paper-based medical record or in the electronic database. Therefore, 
the patients were asked directly about them and the answers were recorded in the data 
collection form. Participants were also asked about the date of diabetes diagnosis since it was 
not available in the medical records. All the data were entered in the data collection form by 
the researcher.  
In some cases, the medications prescribed in the paper-based medical records to a 
patient were not consistent with the prescribed medications shown in the same patient’s 
health record available in the electronic database. In such circumstances, patients were asked 
about the medications they were currently taking to ensure accuracy in reporting the 
medications. In most cases, the patient’s electronic health records were the most reliable 
sources of correct medications prescribed. 
3.11 Data analysis and management 
Data were coded and entered into SPSS version 22 for analysis (IBM Corp. Released 
2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.) Every 
participant was given a unique identifier that was used on all the study instruments and data 
collection forms. Backup of files was regularly conducted, and backup copies were stored in 
separate secure locations. Before conducting the data analysis, descriptive statistics were 
performed to ensure that the percentages of Qataris and Non-Qataris were similar to that of 
our target population. Descriptive analyses were conducted to determine the SOC, medication 
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adherence scores, and diabetes status of the participants. Normality distribution was 
determined for all the variables to decide on the choice of statistical analyses. The variables 
tested for their normality distribution were: SOC, medication adherence, HbA1c, disease 
duration, and total number of prescribed medications. Shapiro-Wilks test and histograms 
were used to assess the normality of the variables. For Shapiro-Wilks, if the p-value for any 
of the variables was less than the alpha (α) level of 0.05, then the variable was considered not 
normally distributed, and if the p-value was more than the α level of 0.05, the variable would 
be considered normally distribution (166). Histograms were examined for each of the 
variable mentioned above to determine if it was normally distributed. If the histogram had a 
bell-shaped curve, the variable was considered normally distributed, otherwise not normally 
distributed (166). The following statistical tests were conducted: 
(i) Chi-square test of association to examine the relation between different baseline 
characteristics. 
(ii) An interrater reliability analysis using the Kappa statistic was performed to determine 
consistency between MMAS-8 and PDC when measuring medication adherence. 
(iii) Spearman rho correlation to determine the relationship between SOC and medication 
adherence, SOC and HbA1c, medication adherence and HbA1c. For all the 
correlations, the α level was set at 0.05 for significance. 
(iv) Spearman rho correlation was conducted to determine the relationship between all 
demographic characteristics with SOC, medication adherence, and HbA1c with an α 
level set at 0.05 for significance. 
(v) Spearman rho correlation was also used to determine the association of disease 
duration with SOC, medication adherence, and HbA1c, and to determine whether or 
not the number of total prescribed medications is associated with SOC, medication 
adherence, or HbA1c. The α was set as 0.05 for significance for all the analyses 
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(vi) Hierarchical regression was performed to assess if SOC could predict medication 
adherence; if SOC could predict HbA1c; and if medication adherence could predict 
HbA1c, in all cases while controlling for demographic and clinical characteristics 
which have a significant correlation with the variables. 
3.12 Pilot study 
A sample of 8 patients was selected from the NCD clinic and used for pilot testing to 
evaluate the feasibility of recruitment and to identify and resolve any issues which might 
arise while conducting the larger study. Both questionnaires were read to the patients. Out of 
the 8 participants, 3 were females, and 5 were males; 7 were at the maintenance stage of 
change and 1 was at the action stage of change. Moreover, 4 had low adherence to their 
antidiabetic medications, 3 had medium adherence, and 1 had high adherence. The mean 
HbA1c of the patients in the pilot study was 7.93 % which is considered an uncontrolled 
diabetes status. According to the results of the pilot study, there was non-significant positive 
correlation between SOC and medication adherence, a non-significant negative correlation 
between SOC and HbA1c, and a non-significant negative correlation between medication 
adherence and HbA1c. Based on the pilot study, no changes were required in the study tools 
before proceeding to the main study. 
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Chapter 4: Results 
4.1 Demographic characteristics of the study participants 
Three hundred eighty-seven patients with T2DM were included in the analysis. The 
mean age ( + sd) of the participants was 54.3 ± 10.2 years, and 153 (39.5%) of them were in 
the age group of 55-65 years old. There were more male participants than females (63% vs. 
37%), and more non-Qataris compared to Qataris (84.8% vs. 15.2%). Additionally, there were 
more Arab participants than Asians or other races (51.9%, 44.2%, and 3.9%, respectively). 
Most of the participants were married (94.6%), and almost half (49.9%) of the participants 
recruited had a bachelor’s degree. Moreover, approximately 36.7% of the participants were 
working as assistants or helpers, while 25.8% were unemployed. Table 1 describes the 
demographic characteristics of the recruited participants.  
 
Table 1: Demographic characteristics of the study participants (n=387) 
Characteristic   Frequency (%) Mean ± SD 
Age (years),  mean ± SD  54.29 ± 10.20 
Age group   
Less than 45 years old 69 (17.8)  
45-54 years old 117 (30.3)  
55-65 years old 153 (39.5)  
Above 65 years old 48 (12.4)  
Sex                                                                                                                         
Male 244 (63.0)  
Female 143 (37.0)  
Nationality   
Qatari 59 (15.2)  
Non-Qatari 328 (84.8)  
Race   
Arab 201 (51.9)  
Asian 171  (44.2)  
Others 15 (3.9)  
Marital status   
Single 13 (3.4)  
Married 366 (94.6)  
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4.2 Clinical characteristics of the study participants 
Of all the 387 participants recruited in the study, 137 (35.4%) had controlled diabetes, 
and 250 (64.6%) participants had uncontrolled diabetes based on the cut off value of 7% of 
HbA1c. The median (IQR) HbA1c of the participants was 7.5% (2.2). In addition, 118 
(30.5%) of the participants were diagnosed with diabetes for less than 5 years, and 117 
(30.2%) for 5-9 years. The most common antidiabetic medication regimen was two oral 
antidiabetics (29.2 %) followed by one antidiabetic (27.1%). Most of the participants had 
other chronic conditions: 77.3% of the participants had dyslipidemia, 66.4% had 
hypertension, and 5.7% did not have any chronic conditions other than diabetes. One hundred 
and seventy nine (46.3%) participants were taking less than 5 medications, whereas 208 
(53.7%) were on polypharmacy (defined as taking 5 or more medications). Table 2 describes 
the relevant clinical characteristics of the participants. 
 Divorced 1 (0.3)  
Widowed 7 (1.7)  
Educational attainment    
Postgraduate 15 (3.8)  
Bachelor 193 (49.9)  
Lower than Bachelor 179 (46.3)  
Occupation   
Professional 88 (22.7)  
Managerial 32 (8.3)  
Assistants and helpers 142 (36.7)  
Unemployed 100 (25.8)  
Retired 25 (6.5)  
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4.3 SOC and medication adherence scores of study participants 
More than 75% of the participants reported that they were in the maintenance stage, 
whereas 14.7% were in the preparation stage. On the other hand, the mean adherence score 
obtained from MMAS-8 was 6.88 ± 1.62, which is classified as medium medication 
adherence. In addition, more than half of the participants self-reported high adherence to their 
antidiabetic medication regimen. Table 3 describes in details the SOC and Morisky 
medication adherence scores of the participants.  
  Table 2: Clinical characteristics of the study participants (n=387)  
Characteristic Frequency 
(%) 
         Median (IQR) 
Diabetes status   
Controlled  137 (35.4)  
Uncontrolled  250 (64.6)  
HbA1c (%)    7.5 (2.2) 
Diabetes duration   
Less than 5 years 118 (30.5)  
5-9 years 117 (30.2)  
10-14 years 74 (19.1)  
15-19 years 50 (12.9)  
20 years and above 28 (7.3)  
Diabetes medication regimen   
1 oral antidiabetic 105 (27.1)  
2 oral antidiabetics 113 (29.2)  
3 oral antidiabetics 57 (14.7)  
4 oral antidiabetics 7 (1.8)  
Insulin only 17 (4.4)  
Insulin and 1 oral antidiabetic 39 (10.1)  
Insulin and 2 oral antidiabetics 36 (9.3)  
Insulin and 3 oral antidiabetics 12 (3.1)  
Insulin and 4 oral antidiabetics 1 (0.3)  
Comorbidities   
Dyslipidemia 299 (77.3)  
Hypertension 257 (66.4)  
Thyroid abnormalities 58 (15)  
Neuropathy 25 (6.5)  
Nephropathy 13 (3.4)  
Others 9 (2.3)  
Number of other medications for comorbidities   
0 22 (5.7)  
1 71 (18.3)  
2 76 (19.6)  
3 94 (24.3)  
4 54 (14)  
≥5 70 (18.1)  
Total number of medications received  5 (3) 
Total number of prescribed medications   
Less than 5 179 (46.3)  
5 or more 208 (53.7)  
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Table 3: Stages of change and Morisky medication adherence scores of the study participants (n=387) 
Variable Frequency (%) Mean ± SD 
Stages of change   
Precontemplation 5 (1.3)  
Contemplation 13 (3.4)  
Preparation 57 (14.7)  
Action 15 (3.9)  
Maintenance 297 (76.7)  
Morisky medication adherence score   
Low adherence (0 to 5.75) 94 (24.3)  
Medium adherence (6 to7) 69 (17.9)  
High adherence (8) 224 (57.8)  
Mean adherence score ± SD  6.88 ± 1.62 
 
4.4 MMAS-8 and PDC 
Kappa statistic was conducted to evaluate the degree of agreement between MMAS-8 
and PDC in measuring medication adherence. PDC was calculated for 117 participants who 
had sufficient data, and the results indicated a significant moderate agreement between 
MMAS-8 and PDC’s assessment of medication adherence [κ = 0.436; (p < 0.001), 95% CI 
(0.504, 0.848)]. 
4.5 Demographic characteristics of the study participants based on stages of change 
Since precontemplation, contemplation, and preparation stages represent participants 
who were not adhering to their antidiabetic medications, the three SOC were grouped 
together when describing the baseline characteristics of the participants. Similarly, action and 
maintenance stages were grouped together when describing the baseline characteristics of the 
participants as both stages indicate that participants were adhering to their medications. There 
were 153 participants in the age group of 55-65 years old; and 127 (83%) of them were in the 
action and maintenance stages. Based on chi-square test, there was a significant association 
between the SOC and age groups of participants (p < 0.05). Most of the Qataris were in the 
action and maintenance stages, and only four (6.8%) of all Qataris were in the pre-action 
stages. In addition, there were more participants in the action and maintenance stages as 
compared to pre-action stages in all ethnicities. There were more Arabs than Asians or other 
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ethnicities in the action and maintenance stages (81.1%, 80.7%, and 73.3%, respectively).  
Out of all married participants, 68 (18.6%) were in the pre-action stages, while 298 (81.4%) 
were in the action and maintenance stages. Based on chi-square test of association, there was 
a significant association between the marital status of participants and their SOC (p < 0.05). 
Table 4 provides a full description of the demographic characteristics of all participants 
according to their SOC. 
Table 4: Description of demographic characteristics of the study participants according to their  stages of 
change (n=387) 
Characteristic Pre-action Action and 
Maintenance 
Total p-value 
Age (years), mean ± 
SD
a 
53.82 ± 5.73 54.76 ± 10.0   
Age group     
 
 
0.88 
< 45 years old 24 (34.8) 45 (65.2) 69 (100) 
45-54 years old 24 (20.5) 93 (79.5)                   117 (100)             
55-65 years old 26 (17.0) 127 (83.0) 153 (100) 
Above 65 1 (2.0) 47 (98.0) 48 (100) 
Gender     
 
0.66 
Male 51 (20.9) 193 (79.1) 244 (100) 
Female 24 (16.8) 119 (83.2) 143 (100) 
Nationality     
 
0.08 
Qatari 4 (6.8) 55 (93.2) 59 (100) 
Non-Qatari 71 (21.6) 257 (78.4) 328 (100) 
Ethnicity     
 
0.06 
Arab 38 (18.9) 163 (81.1) 201 (100) 
Asian 33 (19.3) 138 (80.7) 171 (100) 
Others 4 (26.7) 11 (73.3) 15 (100) 
Marital status     
 
0.04* 
Single 6 (46.2) 7 (53.8) 13 (100) 
Married 68 (18.6) 298 (81.4) 366 (100) 
Divorced 0 (0.0) 1 (100) 1 (100) 
Widowed 1 (14.3) 6 (85.7) 7 (100) 
Educational           
attainment                                         
    
 
 
0.28 
Postgraduate 5 ( 33.4) 10 (66.6) 15 (100) 
Bachelor 40 (20.7) 153 (79.3) 193 (100) 
Lower than Bachelor 30 (16.8) 149 (83.2) 179 (100) 
Occupation     
 
 
 
0.203 
Professional 23 (26.1) 65 (73.9) 88 (100) 
Managerial 9 (28.1) 23 (71.9) 32 (100) 
Assistants and helpers 27 (19.0) 115 (81.0) 142 (100) 
Unemployed 15 (15.0) 85 (85.0) 100 (100) 
Retired 1 (4.0) 24 (96.0) 25 (100) 
Total 75 
(19.4) 
        312 (80.6) 387 (100)  
** p < 0.01 
a independent samples t-test 
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4.6 Clinical characteristics of the study participants based on stages of change 
 Clinical characteristics of the participants were also classified according to their 
SOC. Of all the participants with uncontrolled diabetes, 50 participants (20%) were in the 
pre-action stages, whereas 200 (80%) were in the action and maintenance stages. 
Furthermore, there were 118 participants diagnosed with diabetes for less than five years; out 
of which 29 (24.6%) were in the pre-action stages, and 89 (75.4%) were in the action and 
maintenance stages. There was a significant association between the diabetes duration and the 
participants’ SOC (p< 0.05). Of the patients who had hypertension, 39 (15.2%) were in the 
pre-action stages and 218 (84.8%) were in the action and maintenance stages regarding their 
adherence to medications. There was a significant association between hypertension and the 
SOC of participants (p < 0.05). There was a significant association between dyslipidemia and 
the SOC of participants (p < 0.001). Twenty-two participants were not receiving any 
medications for other comorbidities; 10 (45.5%) of those were in the pre-action stages, and 
12 (54.5%) of them in the action or maintenance stages. A significant association between the 
number of the medications taken for comorbidities and the SOC was shown (p < 0.05). 
Finally out of the 208 participants on polypharmacy (i.e. receiving five or more medications), 
33 (15.8%) were in the pre-action stages, whereas 175 (84.2%) were in the action and 
maintenance stages. There was a significant association between the total prescribed 
medications and the SOC of participants (p < 0.05). Table 5 presents the clinical 
characteristics of participants based on their SOC. 
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4.7 Demographic characteristics of the study participants based on medication 
adherence 
Demographic characteristics were classified based on medication adherence levels. 
Out of the 153 participants in the 55-65 years old age group, the proportion of participants 
with low, medium, and high adherence were 36 (23.5%), 26 (17%), and 91 (59.5%), 
 
 
Table 5: Description of the clinical characteristics of the study participants according to their stages of change 
(n=387) 
Characteristic Pre-action Action and Maintenance  Total p-value 
Diabetes status     
0.89 
 
Controlled (≤ 7%) 25 (18.2) 112 (81.8) 137 (100) 
Uncontrolled (> 7%) 50 (20.0) 200 (80.0) 250 (100) 
Diabetes duration     
 
 
 
 
0.04 * 
Less than 5 years 29 (24.6) 89 (75.4) 118 (100) 
5-9 years 25 (21.4) 92 (78.6) 117 (100) 
10-14 years 8 (10.8) 66 (89.2) 74 (100) 
15-19 years 11 (22.0) 39 (78.0) 50 (100) 
20 years and above 2 (7.1) 26 (92.9) 28 (100) 
Medication regimen     
 
 
 
 
 
0.84 
1 oral antidiabetic 24 (22.9) 81 (77.1) 105 (100) 
2 oral antidiabetics 22 (19.5) 91 (80.5) 113 (100) 
3 oral antidiabetics 9 (15.8) 48 (84.2) 57 (100) 
4 oral antidiabetics 0 (0.0) 7 (100) 7 (100) 
Insulin only 2 (11.8) 15 (88.2) 17 (100) 
Insulin and 1 oral antidiabetic 8 (20.5) 31 (79.5) 39 (100) 
Insulin and 2 oral antidiabetics 6 (16.7) 30 (83.3) 36 (100) 
Insulin and 3 oral antidiabetics 4 (33.3) 8 (66.7) 12 (100) 
Insulin and 4 oral antidiabetics 0 (0.0) 1 (100) 1 (100) 
Comorbidities     
Dyslipidemia 52 (17.4) 247 (82.6) 299 (100) 0.00 ** 
Hypertension 39 (15.2) 218 (84.8) 257 (100) 0.04 * 
Neuropathy 4 (16.0) 21 (84.0) 25 (100)    0.79 
Nephropathy 2 (15.4) 11 (84.6) 13 (100)    0.87 
Thyroid abnormalities 6 (10.9) 49 (89.1) 55 (100)    0.63 
Others 3 (25.0) 9 (75.0) 12 (100) 0.18 
Number of medications for 
comorbidities 
    
 
 
 
 
0.04 * 
0 10 (45.5) 12 (54.5) 22 (100) 
1 15 (21.1) 56 (78.9) 71 (100) 
2 20 (26.3) 56 (73.7) 76 (100) 
3 16 (17.0) 78 (83.0) 94 (100) 
4 7 (87.0) 47 (13.0) 54 (100) 
≥5 7 (10.0) 63 (90.0) 70 (100) 
Total prescribed medications     
 
0.04 * 
<5  42 (23.5) 137 (76.5) 179 (100) 
≥5  33 (15.8) 175 (84.2) 208 (100) 
Total 75 (19.4) 312 (80.6) 387 (100)  
* p < 0.05 
** p < 0.01 
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respectively. Of the 244 males enrolled in the study, 60 (24.6%) had low adherence, 52 
(21.3%) had medium adherence, and 132 (54.1%) had high adherence to their antidiabetic 
medications.  Furthermore, 113 (56.1%) of Arabs, 103 (60.35) of Asians, and 8 (53.3%) of 
other ethnicities who participated in the study had high adherence to their antidiabetic 
medications. There were 366 married participants; 86 (23.5%) had low adherence, 66 (18%) 
had medium adherence, and 214 (58.5%) had high adherence. Chi-square test suggests that 
there was a significant association between the marital status of participants and their 
medication adherence level (p < 0.05). Similarly, there was a significant association between 
the latest educational attainment and the medication adherence levels of participants (p< 
0.001). Table 6 describes the demographic characteristics of the study sample based on 
medication adherence levels.
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Table 6: Description of the demographic characteristics of the study participants according to medication adherence 
scores (n=387) 
Characteristic Low adherence Medium adherence High adherence Total p-value 
Age (years), mean ± 
SD
a 
52.65 ± 4.58 54.68 ± 5.67 58.23 ± 6.25   
Age group      
 
0.74 
<45 years old 24 (34.8) 13 (18.8) 32 (46.4) 69 (100) 
45-54 years old 31 (26.5) 22 (18.8) 64 (54.7) 117 (100) 
55-65 years old 36 (23.5) 26 (17.0) 91 (59.5) 153 (100) 
>65 years old 3 (6.3) 8 (16.7) 37 (77.0) 48 (100) 
Gender      
0.43 Male 60 (24.6) 52 (21.3) 132 (54.1) 244 (100) 
Female 34 (23.8) 17 (11.8) 92 (64.4) 143 (100) 
Nationality      
0.45 Qatari 9 (15.3) 7 (11.9) 43 (72.8) 59 (100) 
Non-Qatari 85 (25.9) 62 (18.9) 181 (55.2) 328 (100) 
Ethnicity     
Arab 52 (25.9) 36 (18.0) 113 (56.1) 201 (100) 
Asian 38 (22.2) 30 (17.5) 103 (60.3) 171 (100) 
Others 4 (26.6) 3 (20.1) 8 (53.3) 15 (100) 
Marital status      
 
0.04 * 
Single 6 (46.2) 3 (23.1) 4 (30.7) 13 (100) 
Married 86 (23.5) 66 (18.0) 214 (58.5) 366 (100) 
Divorced 0 (0.0) 0 (0.0) 1 (100) 1 (100) 
Widowed 2 (28.6) 0 (0.0) 5 (71.4) 7 (100) 
Educational attainment     
 
 
0.00 ** 
Postgraduate 6 (40.0) 3 (20.0) 6 (40.0) 15  (100) 
Bachelor 54 (28.0) 44 (22.8) 95 (49.2) 193 (100) 
Lower than a bachelor 34 (19.0) 22 (12.3) 123 (68.7) 179 (100) 
Occupation      
 
 
0.41 
Professional 31 (35.2) 20 (22.7) 37 (42.1) 88 (100) 
Managerial 9 (28.1) 2 (6.3) 21 (65.6) 32 (100) 
Assistants and helpers 42 (29.6) 22 (15.5) 78 (54.9) 142 (100) 
Unemployed 19 (19.0) 11 (11.0) 70 (70.0) 100 (100) 
Retired 3 (12.0) 4 (16.0) 18 (72.0) 25 (100) 
Total 94 (24.3) 69 (17.9) 224 (57.8) 387 (100)  
* p < 0.05 
** p < 0.01 
a  independent samples t-test 
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4.8 Clinical characteristics of study participants based on medication adherence 
Clinical characteristics were also classified based on medication adherence levels. Out 
of 137 participants who had controlled diabetes, 81 (59.1%) had high medication adherence, 
whereas 143 (57.2%) from those with an uncontrolled diabetes status had high medication 
adherence. There were 118 participants who were diagnosed with T2DM for less than 5 
years; 36 (30.6%) of these had low medication adherence, 22 (18.6%) had medium 
medication adherence, and 60 (50.8%) had high medication adherence. In addition, 162 
(63.1%) of the participants with hypertension had high adherence to their DM medication 
regimens, and there was a significant association between having diagnosis of hypertension 
and adherence to antidiabetic medications (p < 0.05). Of the 299 participants with 
dyslipidemia, 178 (59.6%) had high adherence to their DM regimen and there was also a 
significant association between the presence of dyslipidemia and the participants’ adherence 
to their DM medications (p < 0.05). Surprisingly, 97 (54.2%) of the participants taking less 
than 5 prescribed medications had high medication adherence compared to 127 (61.1%) of 
those participants taking 5 or more medications. Table 7 displays the relevant clinical 
characteristics of all participants recruited based on medication adherence levels. 
Table 7: Description of the clinical characteristics of the study participants based on medication 
adherence scores (n=387) 
Characteristic Low 
adherence 
Medium 
adherence 
High 
adherence 
Total p-value 
Diabetes status      
0.20 Controlled 32 (23.4) 24 (17.5) 81 (59.1) 137 (100) 
Uncontrolled 63 (25.2)  44 (17.6) 143 (57.2) 250 (100) 
Disease duration      
 
 
 
0.95 
<5 years 36 (30.6) 22 (18.6) 60 (50.8) 118 (100) 
5-9 years 33 (28.2) 22 (18.8) 62 (53.0) 117 (100) 
10-14 years 11 (14.9) 17 (23.0) 46 (62.1) 74 (100) 
15-19 years 11 (22.0) 7 (14.0) 32 (64.0) 50 (100) 
≥20 years 3 (10.7) 1 (3.6) 24 (85.7) 28 (100) 
Medication regimen      
 
 
 
 
 
1 oral antidiabetic 29 (27.6) 24 (22.9) 52 (49.5) 105 (100) 
2 oral antidiabetics 32 (28.3) 18 (15.9) 63 (55.8) 113 (100) 
3 oral antidiabetics 11 (19.3) 11 (19.3) 35 (61.4) 57 (100) 
4 oral antidiabetics 0 (0.0) 2 (28.6) 5 (71.4) 7 (100) 
Insulin only 1 (5.9) 1 (5.9) 15 (88.2) 17 (100) 
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Insulin and 1 oral 
antidiabetic 
10 (25.6) 7 (17.9) 22 (56.5) 39 (100)  
1.0 
Insulin and 2 oral 
antidiabetics 
6 (16.7) 5 (13.9) 25 (69.4) 36 (100) 
Insulin and 3 oral 
antidiabetics 
5 (41.7) 1 (8.3) 6 (50.0) 12 (100) 
Insulin and 4 oral 
antidiabetics 
0 (0.0) 0 (0.0) 1 (100) 1 (100) 
Comorbidities   
Dyslipidemia 65 (21.7) 56 (18.7) 178 (59.6) 299 (100) 0.02 * 
Hypertension 51 (19.8) 44 (17.1) 162 (63.1) 257 (100) 0.03 * 
Neuropathy 5 (20.0) 3 (12.0) 17 (68.0) 25 (100) 0.99 
Nephropathy 2 (15.4) 4 (30.8) 7 (53.8) 13 (100) 0.89 
Thyroid 
abnormalities 
9 (16.4) 11 (20.0) 35 (63.6) 55 (100) 0.82 
Others 9 (13.4) 32 (47.8) 26 (38.8) 67 (100) 0.72 
Number of 
medications for 
comorbidities 
     
 
 
 
 
 
0.25 
0 10 (45.5) 2 (9.0) 10 (45.5) 22 (100) 
1 22 (31.0) 12 (16.9) 37 (52.1) 71 (100) 
2 20 (26.3) 17 (22.4) 39 (51.3) 76 (100) 
3 20 (21.3) 16 (17.0) 58 (61.7) 94 (100) 
4 11 (20.1) 9 (16.7) 34 (63.2) 54 (100) 
≥5 11 (15.7) 13 (18.6) 46 (65.7) 70 (100) 
Total prescribed 
medications 
     
 
0.622 <5 51 (28.5) 31 (17.3) 97 (54.2) 179 (100) 
≥5  43 (20.6) 38 (18.3) 127 (61.1) 208 (100) 
Total 94 (24.3) 69 (17.9) 224 (57.8) 387 (100)  
* p < 0.05 
 
4.9 Demographic characteristics of the study participants based on diabetes control 
 Demographic characteristics were described based on the diabetes control of the 
participants (i.e. controlled vs. uncontrolled DM). The mean age of the participants with 
controlled diabetes status was 52.28 ± 10.6 years vs. 56.30 ± 9.8 years for those with 
uncontrolled diabetes status. Among the 69 participants who were less than 45 years old, 21 
(30.4%) had a controlled diabetes, whereas 48 (69.6%) had uncontrolled diabetes. 
Furthermore, 81 (33.2%) of male participants had controlled diabetes compared to 56 
(39.2%) of female participants. In addition, 119 (59.2%) of Arab participants, 123 (71.9%) of 
Asian participants, and 8 (53.3%) of participants of other ethnicities had uncontrolled DM. 
There was a significant association between the latest educational attainment of participants 
and their diabetes status (p < 0.05), whereby 76 (39.4%) of all participants who had a 
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bachelor’s degree had controlled DM. Finally, 33 (37.5%) of the participants who had 
professional occupations had controlled DM when compared with 35 (24.6%) of the 
participants working as assistant or helpers. Consequently, there was a significant association 
between the patients’ occupation and their diabetes control status (p < 0.001). Table 8 
presents all the demographic characteristics of the sample based on diabetes status.  
Table 8: Description of demographic characteristics of study participants based on diabetes status 
(n=387) 
Characteristic Controlled Uncontrolled Total p-value 
Age (years), mean ± 
SD
a
 
52.28 ± 10.6 56.3 ± 9.8   
 
 
0.66 
Age group    
<45 years old 21 (30.4) 48 (69.6) 69 (100) 
45-54 years old 42 (35.9) 75 (64.1) 117 (100) 
55-65 years old 54 (35.3) 99 (64.7) 153 (100) 
>65 years old 20 (41.7) 28 (58.3) 48 (100) 
Gender     
0.24 Male 81 (33.2) 163 (66.8) 244 (100) 
Female 56 (39.2) 87 (60.8) 143 (100) 
Nationality     
0.97 Qatari 21 (35.6) 38 (64.4) 59 (100) 
Non-Qatari 116 (35.4) 212 (64.6) 328 (100) 
Ethnicity     
 
0.03 * 
Arab 82 (40.8) 119 (59.2) 201 (100) 
Asian 48 (28.1) 123 (71.9) 171 (100) 
Others 7 (46.7) 8 (53.3) 15 (100) 
Marital status     
 
0.84 
Single 4 (30.8) 9 (69.2) 13 (100) 
Married 131 (35.8) 235 (64.2) 366 (100) 
Divorced 0 (0.0) 1(100) 1 (100) 
Widowed 2 (28.6) 5 (71.4) 7 (100) 
Educational 
attainment 
    
 
 
0.04 * 
Postgraduate 8 (53.3) 7 (46.7) 15 (100) 
Bachelor 76 (39.4) 117 (60.6) 193 (100) 
Lower than Bachelor 53 (29.6) 126 (70.4) 179 (100) 
Occupation     
 
 
0.00 ** 
Professional 33 (37.5) 55 (62.5) 88 (100) 
Managerial 16 (50.0) 16 (50.0) 32 (100) 
Assistants and helpers 35 (24.6) 107 (75.4) 142 (100) 
Unemployed 40 (40.0) 60 (60.0) 100 (100) 
Retired 13 (52.0) 12 (48.0) 25 (100) 
Total 137 (35.4) 250 (64.6) 387 (100)  
* p < 0.05 
** p < 0.01 
a independent samples t-test 
4.10 Clinical characteristics of the study participants based on diabetes status 
Clinical characteristics were also classified based on the diabetes status of the 
patients. Fifty seven (48.3%) of the participants who were diagnosed with T2DM for less 
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than five years had controlled diabetes, while 46(39.3%) of participants who were diagnosed 
with T2DM for 5-9 years had controlled diabetes. There was a significant association 
between diabetes duration and diabetes status (p < 0.001). Furthermore, of all the participants 
taking one oral antidiabetic medication, 64 (61%) had controlled diabetes, compared to 46 
(40.7%) of all the participants taking 2 oral antidiabetic medications. The findings revealed 
that there was a significant association between the medication regimen for T2DM and the 
diabetes status of the participants (p < 0.001). Finally, 107 (59.8%) of the patients taking less 
than five medications had uncontrolled DM vs. 143 (68.7%) of the patients taking five or 
more medications. Table 9 provides more details regarding the clinical characteristics of the 
study sample based on the diabetes control status. 
 
Table 9: Description of the clinical characteristics of the study participants based on diabetes status 
(n=387) 
Characteristic Controlled Uncontrolled Total p-value 
Disease duration     
 
 
0.00 ** 
<5 years 57 (48.3) 61 (51.7) 118 (100) 
5-9 years 46 (39.3) 71 (60.7) 117 (100) 
10-14 years 17 (23.0) 57 (77.0) 74 (100) 
15-19 years 10 (20.0) 40 (80.0) 50 (100) 
≥20 years 7 (25.0) 21 (75.0) 28 (100) 
Medication regimen     
 
 
 
 
 
0.00 * 
1 oral antidiabetic 64 (61.0) 41 (39.0) 105 (100) 
2 oral antidiabetics 46 (40.7) 67 (59.3) 113 (100) 
3 oral antidiabetics 13 (22.8) 44 (77.2) 57 (100) 
4 oral antidiabetics 1 (14.3) 6 (85.7) 7 (100) 
Insulin only 3 (17.6) 14 (82.4) 17 (100) 
Insulin and 1 oral 
antidiabetic 
3 (7.7) 36 (92.3) 39 (100) 
Insulin and 2 oral 
antidiabetics 
3 (8.3) 33 (91.7) 36 (100) 
Insulin and 3 oral 
antidiabetics 
4 (33.3) 8 (66.7) 12 (100) 
Insulin and 4 oral 
antidiabetics 
0 (0.0) 1 (100) 1 (100) 
Comorbidities     
Dyslipidemia 111 (37.1) 188 (62.9) 299 (100) 0.19 
Hypertension 95 (37.0) 162 (63.0) 257 (100) 0.37 
Neuropathy 5 (20.0) 20 (80.0) 25 (100) 0.09 
Nephropathy 3 (23.1) 10 (76.9) 13 (100) 0.35 
Thyroid abnormalities 21 (38.9)  33 (61.1) 54 (100) 0.92 
Others 
 
 
4 (30.8) 9 (69.2) 13 (100) 0.85 
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Number of medications for 
comorbidities 
    
 
 
 
0.97 
0 6 (27.3) 16 (72.7) 22 (100) 
1 25 (35.2) 46 (64.8) 71 (100) 
2 28 (36.8) 48 (63.2) 76 (100) 
3 34 (36.2) 60 (63.8) 94 (100) 
4 18 (33.3) 36 (66.7) 54 (100) 
≥ 5 26 (37.1) 44 (62.9) 70 (100) 
Total prescribed 
medications 
    
 
0.06 < 5 72 (40.2) 107 (59.8) 179 (100) 
≥ 5  65 (31.3) 143 (68.7) 208 (100) 
Total 137 (35.4) 250 (64.6) 387 (100)  
* p < 0.05 
** p < 0.01 
 
4.11 Association between outcome measures 
Correlation analyses were conducted to investigate the relationship between the 
following pairs of outcome measures: SOC and medication adherence, SOC and HbA1c, and 
medication adherence and HbA1c. The SOC is a categorical variable, while the medication 
adherence and HbA1c scores were both not normally distributed continuous variables. Hence, 
Spearman rho correlation was used to perform the correlation analyses. There was a 
significant positive relationship between SOC and medication adherence (r = 0.728, p < 
0.001). Conversely, there was no significant correlation between SOC and HbA1c (r = - 
0.012, p > 0.05), or between medication adherence and HbA1c (r = - 0.002, p > 0.05). 
4.12 Association of confounding factors with outcome measures 
The correlation of demographic characteristic with outcome measures was 
determined. Table 10 presents the correlations between demographic characteristics with: 
SOC, medication adherence, and HbA1c. There was a significant positive relationship 
between age and SOC (r = 0.276, p < 0.001), and between age and medication adherence (r = 
0.218, p < 0.001). In addition, there was a significant negative relationship between the 
nationality of participants and their SOC (r = - 0.13, p < 0.05), and between their nationality 
and medication adherence (r = - 0.126, p < 0.05). There was also a significant positive, but 
weak relationship between medication adherence and marital status (r = 0.107, p < 0.05). 
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Similarly, there was a significant negative weak relationship between the latest educational 
attainment and medication adherence (r = - 0.202, p < 0.001). Finally, there was a significant 
negative correlation between the occupation of participants and their SOC (r = - 0.159, p < 
0.05), and between occupation and medication adherence (r = - 0.194, p < 0.001).  
Spearman rho correlation was performed to determine the relationship between 
disease duration and the outcome measures. Disease duration had a positive significant weak 
correlation with the SOC of participants (r = 0.167, p ≤ 0.001), their medication adherence (r 
= 0.152, p < 0.05), and their HbA1c scores (r = 0.196, p < 0.001). Table 11 presents the 
results of the correlation analyses between disease duration and SOC, medication adherence, 
and HbA1c. Spearman rho correlation was also performed to determine the relationship 
between total number of prescribed medications and the outcome measures. Total number of 
prescribed medications had a significant positive weak correlation with SOC (r = 0.214, p < 
0.001), medication adherence of participants (r = 0.17, p < 0.001), and their HbA1c scores (r 
= 0.171, p < 0.001). Table 12 shows the results of the correlation analyses between total 
number of prescribed medications and SOC, medication adherence, and HbA1c.
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Table 10: Spearman rho correlation of demographic characteristics and stages of change, medication adherence, and glycated 
hemoglobin 
Characteristic Age Gender Nationality Ethnicity Marital 
status 
Education Occupation 
SOC r = 0.28 r = 0.06 r = - 0.13 r = 0.03 r = 0.09 r = - 0.09 r = - 0.16 
Sig. = 0.00 
** 
Sig.= 0.21 Sig. = 0.01 ** Sig.= 0.48 Sig.= 0.07 Sig. = 0.06 Sig. = 0.002 ** 
Medication 
adherence 
r = 0.22 r = 0.09 r = -0.13 r = 0.03 r = 0.10 r = - 0.20 r = - 0.19 
Sig.= 0.00 
** 
Sig.= 0.09 Sig. = 0.01 ** Sig.= 0.58 Sig.= 0.04* Sig. = 0.00** Sig. = 0.00** 
HbA1c r = -0.08 r = -0.05 r = -0.05 * r = 0.06 r = -0.03 r = - 0.09 r = - 0.01 
Sig.= 0.12 Sig. = 0.30 Sig. = 0.36 Sig.= 0.20 Sig.= 0.59 Sig. = 0.06 Sig. = 0.83 
* p < 0.05 
** p < 0.01 
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4.13 Hierarchical regression between SOC and medication adherence  
After proving a significant positive correlation between SOC and medication 
adherence, hierarchical regression was conducted to investigate if SOC could predict 
medication adherence, while controlling for the following confounding factors which had 
significant correlations with SOC or medication adherence: age, marital status, occupation, 
education, nationality, total prescribed medications, and disease duration. Multicollinearity is 
a violated assumption of hierarchical regression between some confounding factors; hence 
not all were placed in the same model.  Multicollinearity existed between: age and total 
prescribed medications (r = 0.39), occupation and education (r = 0.49), and total prescribed 
medications and diabetes duration (r = 0.372). As a result, two independent hierarchical 
regressions were performed to determine whether SOC could predict medication adherence. 
The first hierarchical regression was done whilst controlling for age, disease duration, and 
Table 11: Spearman rho correlation of disease duration with stages of change, medication adherence and glycated 
hemoglobin 
Characteristic SOC Medication adherence HbA1c 
Disease duration (years) r = 0.167 r = 0.152 r = 0.196 
Sig.= 0.001 ** Sig. = 0.003 ** Sig. = 0.00 ** 
** p < 0.01  
Table 12: Spearman rho correlation of total number of medications prescribed with stages of change, medication 
adherence and glycated hemoglobin 
 SOC Medication adherence HbA1c 
Number of Medications 
prescribed 
r = 0.214 r = 0.17 r = 0.171 
Sig.= 0.00 ** Sig. = 0.001 ** Sig. = 0.001 ** 
** p < 0.01 
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occupation of participants, whereas the second one controlled for the total number of 
prescribed medications, education, and nationality of the participants. All the other 
assumptions were met for both hierarchical regressions: the dependent variable which was 
medication adherence was continuous; there were 2 or more independent variables in both 
regressions, there was an independence of observations, a linear relationship between the 
dependent variable and each independent variable, homoscedasticity, no significant outliers, 
or any high leverage or influential points, no multicollinearity, and finally the residuals were 
normally distributed.  To test the hypotheses that medication adherence can be predicted by 
four variables (age, disease duration, occupation, marital status and SOC), a hierarchical 
regression was performed. Tests for multicollinearity indicated that there was very minimal 
multicollinearity present (VIF= 1.187 for age, 1.152 for disease duration, 1.097 for 
occupation, 1.022 for marital status, and 1.082 for SOC). Results of the regression provided 
partial confirmation for the research hypotheses which states that age is considered a 
covariate when the association between SOC and medication adherence needs to be 
determined ( β= 0.17, t= 3.20, p < 0.001). In addition, SOC significantly predicted 
medication adherence while controlling for age, disease duration, and occupation (β= 0.79, t= 
25.132, p < 0.001). The first model significantly predicted medication adherence, explaining 
8 % of its variance [R= 0.27, R
2 
= 0.08, F (4,382) = 7.74, p < 0.001]. In the second model, 
SOC alone predicted 58% of the variance in medication adherence, and including all the 
variables in the second model significantly improved the model, predicting 65 % of the 
variance in medication adherence [R= 0.81, R
2
= 0.65, F (5,381)= 142.73, p<0.001].  
A second hierarchical regression was performed to determine whether the hypotheses 
stating that medication adherence can be predicted by total prescribed medications, 
education, nationality, and SOC are true or not. There was also a very low level of 
multicollinearity (VIF= 1.106 for total prescribed medications, 1.022 for education, 1.104 for 
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nationality, and 1.053 for SOC). As shown in the first model, total prescribed medications 
and education were able to significantly predict medication adherence [(β = 0.14, t = 2.61, p 
< 0.05) and (β = - 0.17, t = -3.44, p ≤ 0.001) respectively]. The first model as a whole 
significantly predicted medication adherence, explaining 6.0% of its variance [R= 0.25, R
2 
= 
0.06, F (3,383) = 8.23, p < 0.001]. In the second model, SOC predicted 59 % of the variance 
in medication adherence, whereas the second model collectively significantly predicted 
medication adherence by 65% [R= 0.81, R
2 
= 0.65, F (4,382) = 184.75, p < 0.001]. Table 13 
present the results of the two hierarchical regressions. 
  
Table 13: Hierarchical regression analysis of prediction of medication adherence by stages of change, 
controlling for confounding factors 
 Model 1 Model 2 
Variables Β T Sig. Β T Sig. 
First hierarchical regression 
Age 0.17 3.20 0.001 ** -0.01 -0.09 0.93 
Disease duration 0.08 1.54 0.12 0.05 1.39 0.17 
Occupation -0.12 -2.25 0.02 * -0.05 -1.627 0.10 
Marital status 0.02 0.35 0.73 0.02 0.51 0.61 
SOC    0.79 25.13 0.00 ** 
R 0.27 0.81 
R
2
 0.08 0.65 
R
2
 for change 0.08 0.58 
F                     7.74 142.73 
Sig. F change 0.00** 0.00** 
 
Second hierarchical regression 
Total prescribed 
medications 
0.14 2.61 0.009**   -0.01 -0.19 0.84 
Education -0.17 -3.44 0.001** -0.12 -3.83 0.00 ** 
Nationality -0.04 -0.79 0.43 0.01 0.13 0.89 
SOC    0.79 25.9 0.00 ** 
R 0.25 0.81 
R
2 
 0.06 0.65 
R
2
 for change  0.06 0.59 
F 8.23 184.75 
Sig. F change 0.00** 0.00** 
* p < 0.05  
          ** p < 0.01 
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Chapter 5: Discussion 
Based on a thorough review of the literature, this is a novel study that explored the 
association between SOC and medication adherence in a T2DM population. To our 
knowledge, it is also the first study utilizing TTM on diabetic patients in a developing 
country. Other objectives of the study were to determine if SOC or adherence to medication 
could be used to predict HbA1c, and whether disease duration and the total number of 
currently prescribed medications could predict individuals’ adherence to their medication. 
The instruments used in the study had previously been validated and used in other studies. 
The SOC questionnaire was validated using two populations: 161 patients with HIV, and 731 
patients with hypertension (160). In both populations, construct validity (p < 0.001) and 
predictive validity (p < 0.03) were demonstrated. In addition, the English version of MMAS-
8 had high sensitivity and specificity of 93%, and 53% respectively, whereas the Arabic 
version of MMAS-8 demonstrated sensitivity and specificity of 63.9%, and 82.3%, 
respectively. 
5.1 SOC and medication adherence 
Since there was no significant correlation between SOC and HbA1c, or between 
adherence to medication and HbA1c at the bivariate level, we did not proceed with 
multivariate analysis to test the extent that SOC and adherence could predict HbA1c. Other 
objectives were to determine if demographic characteristics, the duration of disease, and the 
total number of currently prescribed medications had an association with SOC, medication 
adherence, or HbA1c. As presented in earlier tables, only the demographic characteristics 
which had a significant correlation with SOC or adherence had to be controlled for while 
determining if SOC was a significant predictor of adherence. The study’s results are similar 
to previous ones. For example, a significant relationship between age and adherence has been 
found in several populations, suggesting that as age increases, adherence to medication 
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increases (112, 167-169). The published literature also suggests that ethnicity had an effect 
on adherence, with Caucasians generally having better adherence than African-Americans, 
Hispanics, and other minorities (120, 170, 171). However, although these papers suggest that 
nationality could influence adherence, most of the studies were conducted in countries with 
mixes of nationalities and ethnicities that differed from that investigated in our study. It is 
therefore difficult to compare our results with other findings.  
Additionally, marital status seems to have a strong effect on adherence to medication, 
with several studies suggesting that marriage has a positive impact on adherence as patients 
who are married often receive support and constant reminders from their spouses to take their 
prescribed medications on time (172-174). Surprisingly, we found that patients with lower 
educational attainment had higher adherence than those with a bachelor’s or postgraduate 
degree. This finding contradicts the results of other studies (175-177) and the expectation that 
patients with higher education have better knowledge of both their disease state and the 
medications they are prescribed. However, there are two previous studies that support our 
findings, showing patients with lower educational levels having better compliance to their 
medication (168, 178). Our finding may result from the patients with limited education 
having more faith in the advice given to them by their health care professionals. Occupation 
also showed a negative effect on medication adherence, with people in occupations classified 
as having higher social status having lower adherence to medications. This contrasts with the 
results of a previous study, which stated that unemployed patients have poorer adherence 
(179). However there seems to be little consistency in this, with the results of studies 
depending on the health care systems in, and the medical practices of, particular countries 
(26). Moreover, disease duration and the total number of currently prescribed medications 
both had significant correlations with SOC and medication adherence. These were therefore 
chosen as confounding factors to be controlled in the hierarchical regression to maintain the 
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internal validity of the study. A few studies agree with our finding, that disease duration is 
associated with medication adherence and patients who have been diagnosed with T2DM for 
a longer period of time, have better adherence to medications (150, 151, 180). As the total 
number of currently prescribed medications increased, adherence to these medications also 
increased. A study by Richard et al. (2003) found patients with T2DM to have high 
medication adherence rates regardless of the total number of medications they were 
prescribed (181). This suggests that physicians must not be restricted in prescribing a limited 
number of medications to patients.  
In addition, our study demonstrates that some demographic characteristics have an 
impact on the SOC about medication adherence in chronic populations, and this contradicts 
the findings of a study, which indicated that not all demographic characteristics influence 
stages of change or medication adherence in a HIV population (63). In the first model in the 
initial hierarchical regression, age, disease duration, occupation, and marital status together 
explained 8 % of the variation in adherence to medication. A second model, containing only 
SOC explained 58 % of the variation. This increased to 65 % when all the other variables 
were also included. In the first model in the second hierarchical regression total prescribed 
medications, educational attainment, and ethnicity were able to explain 6 % of the variation 
in adherence; adding SOC to the second model increased the proportion of variation 
explained to 65 %. The remaining 35 % of unexplained variance in these models is likely to 
be due to other confounding factors that were not included in the model, such as health 
literacy, patient knowledge, and patient-prescriber relationship. Health literacy means the 
ability to read, understand, and remember instructions associated with medications, and to be 
able to act on health information (182). Patients with lower health literacy are usually less 
adherent to their therapy (141), whereas patients with higher health literacy, who can read 
and understand drug labels, tend to be found to be more adherent to their medications (183, 
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184). Patient knowledge is thought to also influence adherence to medication. Often patients 
do not have an adequate level of knowledge about their disease or prescribed treatment, or 
they do not comprehend the importance of the therapies prescribed for their treatment, and 
therefore do not adhere to their medications consistently (114). Other patients lack the 
understanding of the importance and the value of regular clinic visits. Observations in both 
clinics showed several patients with T2DM failing to attend their scheduled appointments in 
the NCD clinics. That might influence adherence to medication because they would seem not 
to understand the importance of these visits. Finally, the patient-prescriber relationship could 
be one of the factors to explain the 34.8% unexplained variance. Several studies concluded 
that patient-prescriber relationship is an important factor, which affects patients’ medication 
adherence (177, 185, 186). Studies have found that good compliance occurs when doctors are 
emotionally supportive, giving reassurance or respect, and treating patients as an equal 
partner (110, 185). Moreover, roughly one out of ten patients who had medium or low 
adherence admitted that it is unintentional non-adherence, where they forgot to take their 
medications only when they are busy at work or with the family but other than that they took 
them regularly. Another reason for medium or low adherence for patients receiving 
metformin was that the physicians told the patients to take the drug with meals, so when they 
skipped meals, they did not take the medication. This indicates that they were not informed 
that they should not skip doses, and they did not understand that the right thing to do was to 
take a small meal instead of skipping a meal, so that they could take metformin. 
Owing to the policies of institutions in Qatar, research related to practitioners and 
health care providers meets more resistance than research related to patient care. It was 
therefore difficult to measure these confounding factors; however it is important to pay 
attention to these factors as they could potentially have confounding effects on adherence to 
medications. 
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The results of our study found that SOC explains 58 % - 59 % of the variation in 
adherence when controlling for demographic or clinical characteristics, though these had 
relatively small impacts on adherence to medication. A thorough review of the literature 
found only one study in T2DM that investigated whether the SOC model could enhance 
adherence to medication; this also encouraged patients to exercise regularly and follow a 
healthier diet (102). The results of the study showed that SOC was able to encourage patients 
to exercise more, and stick to a healthier diet which consequently led to a reduction in 
HbA1c. However, there was little or no change in adherence to medication, except for a 
decrease in the numbers of patients in the precontemplation stage. As this is the only study 
published assessing whether SOC could enhance adherence to medication, or looking for an 
association between these variables in patients with T2DM, the results of this study will be 
compared with other studies that determined the association between SOC and medication 
adherence in other populations with chronic diseases. A study conducted on patients with 
HIV to determine the relationship between SOC and medication adherence had similar results 
to our study (63). That study identified a positive relationship between SOC and adherence to 
ART, with patients with HIV who were identified to be in precontemplation, contemplation, 
or preparation having medication adherence scores roughly 10% lower than the scores 
obtained from patients at the action or maintenance stages. However, in contrast with to our 
results, the study concluded that demographic characteristics were poor predictors of 
adherence. Moreover, the study also suggested using the same two-item SOC questionnaire 
as a screening tool to identify patients who were at earlier SOC because they were not 
adhering to their medication. In addition, another study was done to understand several 
factors associated with non-adherence to antidepressant medications in a setting similar to our 
study (primary care setting) (187). It was found that patients who had lower adherence to 
medications had lower SOC. In fact, the SOC of patients was a significant predictor of 
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adherence to antidepressants (p=0.047), and it was the strongest predictor of medication 
adherence in all other variables tested in the study such as patients satisfaction with their 
physicians, and the type of depression. 
5.2 SOC and HbA1c 
In the study sample, no statistically significant relationship was found between SOC 
and HbA1c (p > 0.5). This result contradicts other studies that have investigated the 
relationship between SOC and HbA1c; they all reported significant negative relationships 
between SOC and HbA1c (102, 103, 105, 108). For example, in a study on patients with 
T2DM, comparing a control group with a group receiving a TTM intervention, the SOC was 
found to be significantly better in helping patients lower their HbA1c and led to better 
diabetes control (105). Three other studies on patients with T2DM have also reported that 
TTM led to a significant reduction in HbA1c (102, 103, 108). All these studies determined 
the SOC of patients with T2DM who were following a healthy diet plan or exercising 
regularly, which led to reductions in HbA1c. This means that, when the TTM model was used 
to identify the SOC of these patients, regarding their diet or exercise, a relationship was 
identified between the SOC and HbA1c. However, in our study the SOC was related to the 
patients’ adherence to the prescribed medications and showed no statistically significant 
relationship with HbA1c. This might be because, even though SOC could predict adherence, 
adherence to treatment for T2DM in our population was unconnected to HbA1c. Another 
possible explanation for our having found no association between SOC and HbA1c is a lack 
of continuity of care in patients with T2DM. A previous study has found that continuity of 
care with a primary care provider who identified patients SOC about diet and exercise led to 
an improved SOC for self-management behaviors, and that continuity of primary health care 
was associated with better glucose control in a diabetic population (152). 
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5.3 Medication adherence and HbA1c 
Contrary to previous studies, this study found no significant association between 
medication adherence and HbA1c (p > 0.5). Most published literature reports significant 
negative correlations between medication adherence and HbA1c. One study stated that for 
every 10% increment in drug adherence, HbA1c decreased by 0.16% (p < 0.001) in a poor 
indigent population (153). In that study African-American patients had higher HbA1c than 
white patients, which led the authors to conclude that minority and indigent groups have less 
controlled HbA1c. The results of our current study suggest that Arabs have more controlled 
HbA1c than Asians (21.2% vs 12.4%) (p < 0.05). Another potential explanation of the lack of 
association between medication adherence and HbA1c is patients failing to attend 
appointments. A previous study found an association between medication adherence and 
HbA1c, and provided evidence that, for patients with T2DM, every appointment they 
attended was associated with a 0.12% decrease in HbA1c (154). Moreover, a published 
systematic review concluded that there is an association between antidiabetic medications 
and HbA1c, regardless of the method used to determine medication adherence. However, this 
association was not always found in low income populations (155). This could be interpreted 
as supporting the results of our study because almost half of the sample reported their highest 
educational attainment to be below a bachelor’s degree and 36.7% were assistants and helpers 
who might be expected to have low incomes. However, if patients with T2DM who have low 
incomes and high adherence to medications have no reduction in HbA1c, other factors which 
affect HbA1c need to be considered. It is possible that these patients are taking their 
antidiabetic medications regularly and consistently, but consuming a diet high in sugar and 
other carbohydrates and not exercising regularly. That could be expected to result in a mean 
HbA1c higher than that observed in other populations who both follow a healthier diet and 
stick to an exercise regime.  
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5.4 Limitations 
Several issues must be considered when interpreting the data presented in the current 
study. First, the SOC model can be criticized for failing to represent the complexities of 
behavioral change (189). For instance, adhering to a particular medication regimen requires 
many different behaviors other than just swallowing a pill: it requires attending appointments 
with the prescribing professional, filling prescriptions, and consistently taking doses (189). It 
is unclear which of these many behaviors the stages of change are intended to target. Instead 
the SOC model is related to the overall medication adherence and based on the answers to the 
questions in MMAS-8. Despite this limitation, our study was able to identify patients at 
higher risk of non-adherence.  Another limitation while using TTM is that progress through 
the SOC is not linear. People can often move from the action or maintenance stages to the 
pre-action stages. Therefore, it is impossible to ensure that participants who were at the 
maintenance stage will always remain to be in this stage. 
The study may also be subject to social desirability bias resulting in the misreporting 
of SOC and medication adherence scores. That would lead to the underestimation of the 
proportions of individuals in the early stages of change and with low medication adherence. 
Self-reported measures do generally tend to yield inflated adherence estimates or advanced 
SOC, so the actual adherence to prescribed medication was probably somewhat lower than 
we observed and there may well have been fewer patients actually at the action and 
maintenance stages. To ensure that the results obtained are not due to social desirability, 
PDC, which is an objective measure, was used to calculate adherence. The scores obtained 
from PDC were similar to those obtained from MMAS-8, suggesting social desirability biases 
were unlikely to have been important.   
Another limitation is that convenience sampling was the method of sampling used to 
recruit participants in the study. The drawback of using convenience sampling is that the 
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sample might not be representative of the population being studied. This undermines the 
ability to make generalisations from the sample recruited to the target population. 
Convenience sampling was the chosen method of sampling due to the limited time of the 
study. Nevertheless, to ensure that the sample is to some extent representative of the target 
population, 10-15 patients were randomly selected every day at the NCD clinic out of a total 
of around 40 patients attending the clinics daily 
Moreover, the SOC determined were only regarding taking the antidiabetic 
medications as prescribed by the patients’ physicians. The SOC related to following a healthy 
diet or exercising was not determined, even though both of these are factors that contribute to 
self-management of T2DM. 
5.5 Future directions and recommendations 
This cross-sectional study gives a good starting point for using the TTM on patients 
with T2DM regarding their medication adherence, but further investigations are required. The 
effectiveness of TTM, as a tool for improving adherence to prescribed medication in our 
target population, has not been fully investigated. Further interventions applying TTM, while 
using the processes of change relevant to the SOC, are needed to determine TTM’s ability, 
usefulness, and impact on medication adherence in a T2DM population. Without conducting 
further research, no clear recommendations can be provided regarding the effectiveness of 
TTM in improving the drug use process. 
Based on observations in both clinics, we suggest applying an educational and 
behavioral self-management intervention in order to increase the patients’ knowledge 
regarding the nature of T2DM, the treatments taken, importance of adherence to medications, 
and to encourage them to regularly attend their appointments in the clinics. This intervention 
will need to incorporate the goals and life experiences of each patient with T2DM to engage 
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and aid them in self-managing their condition. Additionally, there is still no evidence 
suggesting that self-management interventions can significantly reduce mortality and 
morbidity rates in patients with T2DM, therefore it is important to study the effect of self-
management interventions on long term outcomes such as the HR-QOL. 
We also suggest improving the knowledge of patients with T2DM because it can 
influence adherence to medications. It is crucial that each patient understands the pathology 
of diabetes, how their prescribed medications work, and both the diet they need to maintain 
and the foods they need to avoid. Many patients were not aware that carbohydrates break 
down into sugar, so they were only cautious about eating sugar but paid no attention to the 
amounts of carbohydrates they consumed. If patients were educated by health care providers’ 
their adherence to medications would be higher, and they would have better clinical outcomes 
and a better quality of life. 
In addition, determining the medication adherence scores using a tool other than 
MMAS-8 could potentially be important. MMAS-8 has advantages when compared to other 
self-reported measures that determine medication adherence scores, however its’ main 
drawback is that it does not provide a complete evaluation of adherence behaviors. Without 
understanding different behaviors which lead patients to be non-adherent to their medications 
it would be difficult to develop a well-designed intervention that aims to improve adherence. 
Moreover, PHCC should always ensure that patients are capable of using insulin pens. 
It is not unusual for a nurse to repeatedly explain to a patient how to administer insulin, but 
the patient, who only heard the verbal instructions, to remain incapable of doing it 
themselves. In fact, some patients in our study sample who were prescribed oral antidiabetic 
medications and insulin were adhering to their oral medications but not insulin only because 
they did not know how to administer it themselves. These patients would only take the insulin 
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when there was someone available in their homes to give them the pen. We therefore suggest 
that nurses should not only explain use of the pen to new users of insulin, but also watch the 
patients administer it themselves to ensure that they are comfortable doing so. We also 
recommend that the health care team in Mesaimeer health care center devotes more time to 
understanding the importance of encouraging patients with T2DM to always follow up with 
an ophthalmologist because retinopathy is a common major complication in patients with 
diabetes. At the NCD clinic in Mesaimeer the physicians and nurses often overlooked the 
health of the eye of the patient, instead they only asked whether the patients also visiting an 
ophthalmologist and did not assess the results of any follow up visits that occurred. Many 
patients said that they did not visit an ophthalmologist because in Mesaimeer they are only 
available at the morning shift, when many patients are busy at work. It would be worthwhile 
to have an ophthalmologist available during both morning and evening shifts because 
Mesaimeer has the second highest number of patients with T2DM in a primary health care 
center. 
5.6 Conclusion 
The SOC explained 58 % - 59 % of the variance in medication adherence in patients 
with T2DM in a primary health care setting in Qatar; however there was no significant 
relationship found between SOC and HbA1c, nor between medication adherence and HbA1c. 
More than half of the sample was classified as highly adherent to their antidiabetic 
medication, and more than 75% of the sample was at the maintenance stage. Out of all the 
demographic characteristics included in the study, age, nationality, marital status, education, 
and occupation had a significant correlation with either SOC or adherence. Total number of 
currently prescribed medications and disease duration were the only two clinical 
characteristics with statistically significant correlations with both SOC and adherence to 
medication. These results suggest that the two-item SOC could potentially be used to identify 
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patients at risk of low adherence to conduct a TTM intervention to shift those patients to the 
action or maintenance stages, and to enhance their medication adherence, consequently 
leading to better clinical outcomes such as a reduction in HbA1c, and ultimately a better 
health related quality of life. 
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